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ABSTRACT

EFFECT OF ACUPUNCTURE ON MENOPAUSAL MEMORY CHANGES IN
WOMEN WITH BREAST CANCER

By
Elizabeth Cole Collins
May 2013

Dissertation supervised by L. Kathleen Sekula, PhD, APRN, FAAN
Menopausal symptoms are a concern for peri- and postmenopausal women, and
for women who have been treated for breast cancer. Changes in memory are a commonly
reported menopausal symptom which can interfere with daily activities, occurring in
women who experience natural menopause as well as in women who have an abrupt
onset of menopause following treatment for breast cancer. Menopause hormone therapy
may be contraindicated or unacceptable for many women, reinforcing the need for welltolerated, non-hormonal treatments for menopausal symptoms. The purpose of this study
was to examine the efficacy of acupuncture to improve the menopausal symptom of
memory changes in breast cancer survivors, and was a secondary analysis of a placebocontrolled, randomized clinical trial. The Framework for Interactions between the
Individual and the Environment was the conceptual framework that guided the study.
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Subjects in the parent study were randomized to either the experimental group
(symptom-specific acupuncture), control group (non-symptom-specific acupuncture), or
enhanced usual care group (instruction on health-related topics). Each group received
twelve intervention sessions over an 8-week period. Sixty subjects indicating a positive
response to memory items on instruments at baseline were selected for this secondary
analysis. The Daily Symptom Diary, Kupperman Index, and Menopause-Specific Quality
of Life Questionnaire (MENQOL) measured frequency or severity of perceived memory
changes at baseline, midpoint, and end of treatment.
Frequency distributions were used to summarize the data. There were no
statistically significant results from the Daily Symptom Diary. Improvement in the
enhanced usual care group compared to the acupuncture groups was seen on the
Kupperman Index, and validity concerns for this instrument were reviewed. Analysis of
the MENQOL data revealed more positive change in the acupuncture groups in
improvement of memory than in the enhanced usual care group. These findings support
the need for further exploration of targeted interventions such as acupuncture to improve
memory difficulties for menopausal women and breast cancer survivors, particularly as
advances are made in the understanding of the mechanisms of cognitive change.
Acupuncture remains promising as a non-hormonal treatment for menopausal symptoms
and merits further investigation.
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Chapter 1
Introduction

Background of the Study
Menopausal symptoms are a concern for peri- and postmenopausal women, and
for women who have been treated for breast cancer. Vasomotor symptoms (hot flashes
and night sweats) affect approximately 65% of breast cancer survivors (Carpenter et al.,
1998; Couzi, Helzlsouer, & Fetting, 1995; Mom, Buijs, Willemse, Mourits, & de Vries,
2006), with many women rating them as severe (Carpenter et al., 1998; Couzi et al.,
1995).
Changes in memory are another common menopausal symptom reported by women
that can affect quality of life. More than half of midlife women identify memory
problems, with many indicating interference with day-to-day functioning (Betti et al.,
2001; Gold et al., 2000; Mitchell & Woods, 2001, 2011; Simon & Reape, 2009; Weber,
Mapstone, Staskiewicz, & Maki, 2012; Woods & Mitchell, 2011). Memory changes
occur both in women who experience natural menopause as well as in women who have
an abrupt onset of menopause following treatment for breast cancer (Knobf, 2001).
Menopausal symptoms have been attributed to decreasing levels of circulating
estrogen, though the mechanism behind these symptoms is not completely understood
(Fritz & Speroff, 2011; Pachman, Jones, & Loprinzi, 2010). Estrogen produces a variety
of actions on non-reproductive functions in the human brain, including those important
for memory (Dumas, Hancur-Bucci, Naylor, Sites, & Newhouse, 2008; McEwen, 2002;
McEwen, Gould, Orchinick, Weiland, & Woolley, 1995). Clinical studies of the
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influence of estrogen on cognition suggest that estrogen is a factor in maintaining aspects
of memory in women (Sherwin, 2003). While a number of studies have shown that
menopausal hormone therapy may have specific positive cognitive effects in
symptomatic menopausal women (Kampen & Sherwin, 1994; LeBlanc, Janowsky, Chan,
& Nelson, 2001; Phillips & Sherwin, 1992; Sherwin, 1988), the safety of menopausal
hormone therapy in women following a diagnosis of breast cancer is of concern
(Holmberg et al., 2008; Mom et al., 2006). However, study findings are inconsistent
regarding risk for breast cancer recurrence associated with menopausal hormone therapy
(Col, Kim, & Chlebowski, 2005; DiSaia, Brewster, Ziogas, & Anton-Culver, 2000;
Figueiredo et al., 2008).
Complementary and alternative medicine (CAM) therapies have been broadly
used by women in the management of menopausal symptoms (Bair et al., 2008; Kessel &
Kronenberg, 2004) as well as by women with breast cancer (Boon, Olatunde, & Zick,
2007; Burstein, Gelber, Guadagnoli, & Weeks, 1999; Fenlon & Rogers, 2007; Ganz et
al., 2002; Hunter et al., 2004; Lengacher et al., 2006). In a study of 222 women treated
for early stage breast cancer, nearly 57% used at least one CAM therapy, including
acupuncture (Wyatt, Sikorskii, Wills, & Su, 2010). Breast cancer survivors with
treatment-induced menopause may avoid pharmacologic interventions for symptom
management after experiencing chemotherapy (Knobf, 2002). A widely practiced
therapeutic intervention in the United States, acupuncture has been proposed as a nonhormonal treatment alternative for menopausal symptoms (Borud et al., 2009; Wyon,
Wijma, Nedstrand, & Hammar, 2004).
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It is estimated that there will be 232,340 newly diagnosed cases of breast cancer
in women in the United States in 2013 (Siegel, Naishadham, & Jemal, 2013). The
majority of these women are diagnosed at an early stage and 90% can expect to live 5
years or more. Scientific testing of alternative and complementary therapies for
management of menopausal symptoms is needed, particularly for women who experience
menopause following treatment for breast cancer and others for whom menopausal
hormone therapy may not be appropriate or acceptable (NIH State-of-the-Science Panel,
2005).

Purpose of the Study
A secondary analysis of an existing data set from a randomized controlled trial
was conducted. The purpose of this study was to examine the efficacy of acupuncture to
improve memory in breast cancer survivors with menopausal symptoms.
The specific aims of this study were:
1. Examine the treatment effect of acupuncture for menopausal symptom relief using
changes in memory as an outcome measure.
2. Examine the effect of acupuncture on memory changes in relationship to
improvements in hot flashes and night sweats.
The conceptual framework that guided this study is the Framework for
Interactions between the Individual and the Environment (Elliott & Eisdorfer, 1982). It
will be described in the review of the literature.
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Research Questions
Question 1. What are the effects of menopausal symptom-specific acupuncture
on memory in breast cancer survivors with menopausal symptoms?
Hypothesis 1a. Menopausal symptom-specific acupuncture will improve
perceived memory changes as measured by self-reports compared to enhanced usual care
(education).
Hypothesis 1b. Non-symptom-specific acupuncture will improve perceived
memory changes as measured by self-reports compared to enhanced usual care
(education).
Question 2. Is there a relationship between improvements in hot flashes/night
sweats and perceived memory changes in breast cancer survivors with menopausal
symptoms?

Assumptions
The following are the assumptions upon which this study was based.
1. Data collection instruments were completed accurately by the subjects
who participated in the parent study.
2. Information provided by the participants in the parent study was truthful.
3. Instruments used in the parent study were valid and reliable in this population.

Limitations
The following are limitations of this study.
1. Participants were self-selected.
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2. Data were self-reported.
3. The sample may not be representative of all breast cancer survivors with
menopausal symptoms.
4. There was potential for recall bias in the parent study.

Definition of Terms
The following are terms used in this study.
Menopause. Menopause is the permanent cessation of menses resulting from
reduced levels of ovarian hormone secretion. This can occur naturally or be induced by
surgery, chemotherapy, or radiation. Natural menopause is defined as 12 months of
amenorrhea not associated with a physiologic or pathologic cause (Nelson et al., 2005).
Menopausal transition. In an effort to improve comparability of studies of
midlife women, a standardized staging system for reproductive aging and the menopause
transition has been developed for use in research and clinical settings (Harlow et al.,
2012; Soules et al., 2001). The menopausal transition follows a predictable pattern
spanning several years‟ time, and begins with variations in menstrual cycle length in
response to variations in the level of follicle stimulating hormone. The stages of the
menopausal transition can be described by the following terms. Premenopause is the time
up to the beginning of perimenopause, but may also be used to define the time up to the
final menstrual period. Perimenopause is the time around menopause when menstrual
cycle and endocrine changes are taking place, but 12 months of amenorrhea has not yet
occurred. This includes early menopausal transition and late menopausal transition
stages, each defined by specific menstrual and endocrine characteristics. Postmenopause
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actually begins at the time of the final menstrual period, but is not recognized until after
12 months of amenorrhea (Harlow et al., 2012; Nelson et al., 2005; Soules et al., 2001).
Cognition. Cognition is a comprehensive term comprising the following mental
processes by which knowledge is acquired, stored, and used: attention, perception,
working memory, executive function, spatial ability, language, learning, memory - figural
and verbal (Loring, 1999).
Memory. There are various forms of memory which implicate different parts of
the brain and different neurophysiologic processes. Episodic memory differs from other
major memory systems, which include semantic memory, procedural memory, and
working (short-term) memory (Tulving, 2003).
Episodic memory. This form of memory involves exposure to new information
during a discrete event (or episode), followed by conscious recollection of the
information at a later time. The interval between exposure and recall can be minutes,
days, or years. Episodic memory for information that is encoded through words or
retrieved through verbal maneuvers is described as episodic verbal memory
(Henderson, 2009, 2011).
Semantic memory. Learned memory of facts and concepts, such as the capital of
a country, describes semantic memory which is strongly language-based. In contrast to
episodic memory, details of time, place and context are not crucial to semantic memory
(Craik, 2003).
Procedural memory. This form of memory allows for the performance of
activities or skills, such as riding a bicycle, and does not require explicit recollection of
the past (Balota, Dolan, & Duchek, 2000).
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Working memory. Working memory refers to information held and manipulated
in the mind for a short period of time, and incorporates executive functions such as
attention and sequencing (Baddeley, 1996; Craik, 2003).
Memory testing. Different measures of memory tap different aspects of the
memory systems (Lockhart, 2003). Several types of memory tests frequently used in
research studies on memory changes in menopause are included here. Memory testing
may also be referred to as neurocognitive or neuropsychological testing.
Recall tests. The recall of a list of words or a paragraph with or without cues or
reminders is often used to study episodic verbal memory. Techniques for measuring
episodic verbal memory include word-list learning, paragraph or story recall, and
immediate and delayed recall (Craik, 2003).
Verbal fluency. Verbal fluency is the speed and ease of verbal production, and is
typically measured by the quantity of words generated within a time limit in response to a
stimulus or within a restricted category (e.g., animals or groceries). A test of verbal
fluency calls on semantic memory, and reveals organization of thinking (Lezak,
Howieson, & Loring, 2004).
Memory span. Tests of memory span require a person to repeat back accurately a
list of digits or words over several trials. Solving a verbal problem, doing mental
arithmetic, or completing a test of memory span involve working memory (Craik, 2003).
Perceptual speed. This test examines aspects of visual recognition and attention.
It is a picture matching test in which visuoperceptual accuracy and speed in making
perceptual judgments influence performance (Lezak et al., 2004; Strauss, Sherman, &
Spreen, 2006). Perceptual speed can also be referred to as processing speed.
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Memory changes.
Terminology. Various terms were used to describe women‟s experiences with
memory during the menopausal transition. Examples included here are from several
research instruments, research reports, and other publications noted in this study:
undesirable changes in memory; types of memory changes such as: can‟t recall words or
phone numbers, forgot purpose of behavior, concentration problems, need memory aids,
forgot events (Mitchell & Woods, 2001); cognitive disturbances (Nelson et al., 2005);
from the Daily Symptom Diary and Kupperman Index, both used in this study: loss of
concentration (Kupperman, Blatt, Wiesbader, & Filler, 1953; Kupperman, Wetchler, &
Blatt, 1959); from the Menopause-Specific Quality of Life Questionnaire used in this
study: experiencing poor memory (Hilditch et al., 1996); from the Study of Women‟s
Health Across the Nation (SWAN) symptom inventory: forgetfulness (Gold et al., 2000);
from the Cancer Rehabilitation Evaluation System questionnaire: difficulty remembering,
difficulty concentrating, difficulty thinking clearly (Ganz et al., 1996); from the Breast
Cancer Prevention Trial Symptom Checklist: forgetfulness, difficulty concentrating,
easily distracted (Ganz et al., 2002).
Measurement. In this study, memory changes were self-reported. On the
Kupperman Index, loss of concentration is rated by severity on a scale of 0 – 3, as not
present, mild, moderate or severe. On the Daily Symptom Diary, loss of concentration is
noted by frequency defined as the number of times per day it occurs. On the MenopauseSpecific Quality of Life Questionnaire, experiencing poor memory is rated on a scale of
0 – 6, from not at all bothered to extremely bothered.
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Hot flashes. A hot flash (or flush) is a spontaneous sensation of warmth,
sometimes associated with perspiration, resulting from a vasomotor response to declining
estrogen levels (Nelson et al., 2005). Hot flashes are defined as recurrent, transient
periods of flushing, sweating and a sensation of heat, which may be accompanied by
palpitations, a feeling of anxiety, and occasionally followed by chills. The severity,
duration and frequency of hot flashes can vary both within and between individuals. Hot
flashes are a phenomenon of women who are in transition to menopause, or who have
become postmenopausal, either naturally or because of a medical or surgical intervention
(Kronenberg, 1990).
Vasomotor symptoms of hot flashes and night sweats are sudden sensations of
intense heat with sweating and flushing typically lasting 5 to 10 minutes. Hot flashes
occur with a greater frequency and severity in premenopausal women who experience a
sudden onset of menopause due to oophorectomy, or medical conditions or treatments
that result in diminished ovarian hormone production (NIH State-of-the-Science Panel,
2005).
Measurement. In this study, hot flashes were self-reported. On the Kupperman
Index, hot flashes are rated by severity on a scale of 0 – 3, as either not present, mild,
moderate or severe. On the Daily Symptom Diary, hot flashes are rated by frequency or
the number of times per day they occur. On the Menopause-Specific Quality of Life
Questionnaire, hot flashes are rated on a scale of 0 – 6, from not at all bothered to
extremely bothered.
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Night sweats. Night sweats are hot flashes which occur at night, often while
sleeping (Nelson et al., 2005). Night sweats have been referred to as hot flashes during
sleep or during sleeping hours, or as nighttime hot flashes (Maki et al., 2008).
Measurement. Night sweats were self-reported in this study. They are rated as
described under hot flashes on the Daily Symptom Diary and the Menopause-Specific
Quality of Life Questionnaire. Night sweats are not reported on the Kupperman Index.
Hormone therapy.
Menopausal hormone therapy. Hormone therapy for treatment of menopausal
vasomotor symptoms consists of either estrogen in combination with a progestin, or
estrogen alone.
Adjuvant hormone therapy. Hormonal therapy, also called endocrine therapy,
used in the treatment of breast cancer refers to treatment with a selective estrogen
receptor modulator, usually tamoxifen, or an aromatase inhibitor, such as anastrozole.
Complementary and alternative medicine. Complementary and alternative
medicine (CAM) includes a range of diverse medical and health care systems, practices,
and products that are not usually considered part of conventional medicine. The National
Center for Complementary and Alternative Medicine divides CAM practices into the
following categories: mind and body medicine, natural products, energy medicine,
manipulative and body-based practices, movement therapies, and whole medical systems.
Acupuncture is considered to be a practice of mind and body medicine, but also plays a
role in manipulative and body-based practices and energy medicine. Traditional Chinese
medicine, an example of a whole system developed in a non-Western culture, includes
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the practice of acupuncture as one of its key components (NCCAM, 2011; Nedrow et al.,
2006).
Acupuncture. Acupuncture can be defined as the insertion of one or more
needles into specific sites on the body surface for therapeutic purposes. These sites,
called acupuncture points, can also be stimulated with heat, electrical currents, pressure,
or laser light (Ernst, 2006). Acupuncture points are thought to stimulate the central
nervous system to release chemicals that change the experience of pain, or that cause the
release of other chemicals. Possible mechanisms for these biochemical changes are
conduction of electromagnetic signals, activation of opioids, and changes in the brain,
such as release of neurotransmitters (Ma, 2004; Nestler & Dovey, 2001).
Symptom-specific acupuncture. Symptom- or site-specific needling occurs at
classical acupuncture points specific for a dysfunction or disease. These points have
usually been derived from traditional Chinese ideas about illness. Most clinical trials use
this approach (C. Vincent & Richardson, 1986). Menopausal symptom-specific
acupuncture was used in this study.
Placebo control acupuncture. Various types of acupuncture may be used as a
placebo control. Used in this study, non-symptom-specific acupuncture (nonspecific
acupuncture) consists of needling valid acupuncture points that do not address the target
symptoms. Sham acupuncture is needling at sites off any acupuncture channels, also
called meridians. Use of placebo needles simulates the sensation of acupuncture without
skin penetration. Placebo needles may be used at valid or sham points (Nir, Huang,
Schnyer, Chen, & Manber, 2007).
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Significance of the Study
Adjuvant chemotherapy and/or hormonal therapy are commonly prescribed as
treatment for women with breast cancer, and may precipitate suppression of ovarian
function and the onset of menopausal symptoms (Pérez-Fidalgo et al., 2010). Women
who are premenopausal at the time of breast cancer diagnosis may experience
consequences of attention, learning, and memory deficits at the same time they may be
developing careers, maintaining relationships, and raising children (Bender, Paraska,
Sereika, Ryan, & Berga, 2001). These women may be at greater long-term risk of
cognitive impairment due to an extended lifetime exposure to a reduced estrogen
environment (Nappi et al., 1999; Shuster, Rhodes, Gostout, Grossardt, & Rocca, 2010),
as well as more severe vasomotor symptoms due to an abrupt decline in estrogen
(Carpenter, Johnson, Wagner, & Andrykowski, 2002; Fenlon & Rogers, 2007; Knobf,
2006).
Several well-controlled studies have shown that estrogen treatment maintains
verbal memory in healthy women, although the size of the effect is modest (Sherwin,
1997). Women with spontaneous complaints of memory deficits give credence to the
significance of these symptoms in everyday life, notwithstanding their magnitude as
measured with neuropsychological testing. Clinical experience suggests that women are
more reluctant to endure the classic menopausal symptoms that often influence daily
functioning such as hot flashes, insomnia, and disturbances in memory. Memory takes on
more importance in light of the increase in female life expectancy (Sherwin, 1998), and
in the number of long-term breast cancer survivors who experience cognitive changes
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secondary to cancer diagnosis and treatment (Ganz, 1998; Ganz, Greendale, Petersen,
Kahn, & Bower, 2003; Wefel, Witgert, & Meyers, 2008).
Alternative interventions for the management or attenuation of changes in
memory in women following breast cancer treatment have not been sufficiently tested. At
a consensus development conference, the National Institutes of Health encouraged further
studies of the clinical value of acupuncture for various health conditions (NIH Consensus
Development Panel on Acupuncture, 1998). The results of this study may provide breast
cancer survivors with a nonhormonal treatment option for menopausal symptom
management.

13

Chapter 2
Review of the Literature

Introduction
The purpose of this study is to examine the efficacy of acupuncture in improving
memory in breast cancer survivors who are experiencing menopausal symptoms. This
chapter reviews the literature pertinent to the menopausal symptom of memory changes
as it affects women in the menopausal transition, women who are breast cancer survivors,
and women whose menopause has been induced by breast cancer treatment, as well as
how the symptoms of hot flashes and memory changes interact during the menopausal
transition. Literature on acupuncture used as a therapy for menopausal symptoms in
healthy women and breast cancer survivors is reviewed. Lastly, the theoretical framework
that underpins this study is presented.

Menopausal Memory Changes
Change in memory is one of a constellation of symptoms experienced by
menopausal women. Little research has been done about the natural history of
development of cognitive changes as perceived by women as they approach menopause.
In an effort to describe these types of changes, Mitchell and Woods (2001) interviewed
230 women enrolled in the Seattle Midlife Women‟s Health Study. Participants had a
mean age of 46.7 years and were identified as being in early, middle, or late menopausal
transition stages. Sixty-two percent reported memory changes, which were categorized as
problems recalling words and numbers, forgetting everyday behaviors, need for memory
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aids, forgetting events, and concentration problems. These changes were most frequently
attributed to role burden and stress, getting older (though not associated with an actual
age or menopausal status), and health problems. The women did not directly link memory
changes to hormones or menstrual cycle changes. Woods, Mitchell and Adams (2000)
studied participants in the Seattle Midlife Women‟s Health Study (n = 205) who
completed the Memory Functioning Questionnaire. Perceived memory functioning was
more closely related to perceived health status, depressed mood, and perceived stress than
to perimenopausal classification or age.
In the Study of Women‟s Health Across the Nation (SWAN), a cross-sectional
survey of menopausal and other symptoms was completed in a multiracial, multiethnic
sample of 12,425 women aged 40-55 years (Gold et al., 2000). Crude prevalence odds
ratios were calculated for associations between symptoms and selected characteristics,
including age, education, race/ethnicity, menstrual status, and physical activity. Most
women were pre- or early perimenopausal, with the prevalence of symptoms varying
more by menstrual status than by age. All symptoms were more frequent in women who
were not premenopausal, with more than 40% of early peri-, late peri-, and
postmenopausal women reporting forgetfulness compared with 31.2% of premenopausal
women. The prevalence of forgetfulness was higher in women who were not employed
full time, had less than a high school education, and those reporting less physical activity.
In midlife women, many studies measuring cognitive performance using
neurocognitive testing include assessment of episodic verbal memory (also referred to as
verbal memory) because of evidence that estrogen may play a particular role in
maintaining or enhancing verbal memory in surgically menopausal women (Phillips &
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Sherwin, 1992; Sherwin, 1988; Sherwin & Tulandi, 1996), as well as its relevance to
dementia risk (Maki et al., 2010). Episodic verbal memory involves exposure to new
information during an event (or episode), followed by conscious recollection of the
information at a later time. Effort is required on the part of the rememberer for encoding
and retrieval of the information. The interval between exposure and recall can be
minutes, days, or years (Henderson, 2009). Episodic verbal memory is mediated by the
hippocampus and prefrontal cortex (O'Reilly & Rudy, 2001; Wheeler, Stuss, & Tulving,
1997), regions of the brain rich in estrogen receptors and potentially susceptible to
decreases in estrogen (Morrison, Brinton, Schmidt, & Gore, 2006). Structural changes in
the hippocampus concomitant with increased verbal memory performance have been seen
during the menstrual cycle when estrogen levels are high (Protopopescu et al., 2008), and
postmenopausal estrogen administration has been associated with greater hippocampal
size (Eberling et al., 2003). The types and patterns of cognitive improvement seen in
clinical studies using estrogen therapy suggest that estrogen‟s effect may be specific to
the frontally mediated cognitive processes involved in verbal recall and learning (Keenan,
Ezzat, Ginsburg, & Moore, 2001).
Several studies have examined cognitive performance as women transition to
menopause. Some of these include women who have experienced natural menopause as
well as those with surgically-induced menopause, and/or women taking menopausal
hormone therapy.
In a cross-sectional analysis of 326 women (xˉ age = 56.7) in the Melbourne
Women‟s Midlife Health Project, menopausal status was categorized as early or late
menopausal transition, and early or late postmenopause (Henderson, Guthrie, Dudley,
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Burger, & Dennerstein, 2003). Forty-six percent of women were in the early
postmenopause group. Current users of menopausal hormone therapy (MHT) comprised
23% of the women in the study. An episodic verbal memory task using a word list with
immediate and delayed recall was administered. Memory did not vary significantly with
menopausal status, and was not associated with current or prior use of MHT, or with
MHT duration. In the 139 postmenopausal women in the study who were never-users of
MHT, memory scores were unrelated to years since the final menstrual period.
A group of 108 healthy, naturally postmenopausal women enrolled in the
longitudinal, population-based Betula study on memory, health and aging in Sweden
were examined based on their use of MHT (Yonker et al., 2006). There were 43 MHT
users (xˉ age = 58), and 65 non-MHT users (xˉ age = 59.9). Five different hormone
preparations were being used: estriol alone, two estriol preparations each with a different
progestin, and two estradiol preparations each with a different progestin. Women
completed cognitive tasks including episodic verbal memory, verbal fluency, semantic
memory, and spatial visualization. There was a significant effect of MHT on episodic
verbal memory (F = 10.15, p < .002) and verbal fluency tasks (F = 3.82, p < .05), with
MHT users performing better than non-users. The correlation between serum estradiol
levels and episodic verbal memory was also significant (r = 0.22. p < .02). The effect of
MHT on other memory tasks did not reach significance, nor did estradiol levels correlate
with other types of cognitive performance.
A cross-sectional study of 1657 women (xˉ age = 49.7) in the SWAN study was
conducted to examine cognitive function in the menopause transition (Luetters et al.,
2007). Menopausal status categories were pre-, early peri-, late peri-, and
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postmenopausal. Women completed measures of verbal episodic memory, working
memory, and processing speed, and a symptom checklist and interview. After adjustment
for variables including age, education, and menopausal symptoms, no relationship was
found between cognitive test performance and menopausal stage. Serum hormone levels
were not related to cognitive performance in any menopausal stage.
Herlitz and colleagues (2007) looked at cognitive performance across the
menopause transition in a group of 242 women in the Swedish Betula study.
Premenopausal (n = 129, xˉ age = 46.6), perimenopausal (n = 58, xˉ age = 51.6), and
postmenopausal (n = 55, xˉ age = 53.8) women were tested on cognitive measures of
episodic verbal and semantic memory, verbal fluency, spatial visualization, and face
recognition. MHT users were excluded, and 15 women in the postmenopausal group had
experienced surgical menopause. There were no differences among the groups on any
areas of cognitive performance, nor was there a relationship between serum estradiol
levels and cognitive performance.
A large British cohort of women (n = 1261) followed regularly since their birth in
1946 underwent cognitive testing using three different measures at age 53 (Kok et al.,
2006). Most of those in natural menopausal transition were postmenopausal (n = 405) or
perimenopausal (n = 206), with 73 still premenopausal. The remaining women had
undergone hysterectomy and/or oophorectomy (n = 264) or were taking MHT (n = 313).
Perimenopausal women had higher scores than postmenopausal women on all measures.
No detrimental effect of surgery or MHT was seen. There was no effect of menopause
status found on verbal memory, which was assessed using a word list with immediate and
delayed recall.
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Weber and Mapstone (2009) studied 24 perimenopausal women (xˉ age = 49.7) to
determine a relationship between subjective reports of memory problems and
performance on objective cognitive tests. Participants completed a cognitive test battery,
and self-report questionnaires on depression, memory, quality of life, and overall health.
Seventy-nine percent reported some degree of memory loss, with 46% reporting this as
moderately severe. Overall, normal memory function was seen on objective testing.
Women with more memory complaints did not differ in vasomotor symptoms or hormone
levels from those with fewer complaints. However, reported memory complaints were
associated with poorer performance on tests of immediate verbal memory (encoding) (r =
0.48, p = .02) and working memory (r = -0.44, p = .03), and greater depressive symptoms
(r = -0.71, p = .00), but not with delayed verbal recall (retention), suggesting disruption
of attentionally mediated memory processes. The investigators (Weber et al., 2012)
replicated this study with a larger sample of perimenopausal women (n = 75, xˉ age =
49.3). Of these women, 67% reported some memory loss, with 41% reporting at least
moderately severe memory loss. Subjective memory complaints were associated with
greater depressive symptoms and worse performance on measures of working memory
and complex attention/vigilance, but not on tests of verbal memory. Memory complaints
and test performance were not related to hormone levels.
In a rural, community-based study, 495 premenopausal Taiwanese women were
followed for 18 months, with neuropsychological testing at baseline and study end (Fuh,
Wang, Lee, Lu, & Juang, 2006). Of these women, 114 who progressed to perimenopause
(xˉ age = 47.1) were compared with the remaining 381 premenopausal women (xˉ age =
44.7). At follow-up, performance on all tests improved in both groups. Multiple linear
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regression was used to compare mean change in cognitive function between groups.
Menopausal transition was significantly associated with less improvement on a verbal
fluency task (p < .001), but no significant differences were found on any other measures,
including a verbal memory test of word-list learning with immediate and delayed recall,
visual recognition, visuomotor tracking, and working memory.
A cohort of 803 women, aged 42 to 52 years, in the Chicago site of the SWAN
study who were pre- or early perimenopausal at baseline, and not current users of
hormone preparations, completed brief measures of working memory and perceptual
speed annually over a two year period (Meyer et al., 2003). Verbal memory measures
were not included. Menopausal status endpoint categories were pre-, early peri-, late
peri-, and postmenopausal. During the time of observation, 59% had changed menopausal
stage, including 15% who became postmenopausal, with 16% changing menopausal
status more than once. Linear mixed effects models were used to examine changes over
time, and whether rate of change differed by menopausal status. A small but significant
improvement in working memory (p < .0001) and perceptual speed (p = .002) was seen
with aging, but there was no significant incremental change as women progressed from
one menopausal stage to another. In pre- and early perimenopausal women, working
memory (p = .02; p = .0001, respectively) and perceptual speed (p = .03; p = .046,
respectively) improved slightly but significantly over time, with late perimenopausal
women also improving in perceptual speed (p = .01). Postmenopausal women showed
significant decrease over time only in perceptual speed (p = .02). The researchers
concluded that transition through natural menopause is not associated with a significant
decline in either working memory or perceptual speed.
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Greendale et al. (2009) studied 2362 women from the SWAN study over four
years (xˉ age = 50 at final testing) looking at longitudinal performance on annual tests of
episodic verbal memory, working memory, and processing speed. Menopausal status
categories were pre-, early peri-, late peri-, postmenopausal not taking MHT, and
postmenopausal currently taking MHT (initiated after final menstrual period). Pre-, early
peri-, and postmenopausal women scored higher with repeated testing of processing
speed, but scores of late perimenopausal women did not improve over time. Verbal
memory scores on delayed recall improved with repetition for pre- and postmenopausal
women, but scores of early and late perimenopausal women did not improve. Former
hormone users (prior to final menstrual period) had better processing speed and verbal
memory, in contrast to current postmenopausal hormone users whose processing speed
and verbal memory performance were worse over time compared to premenopausal
performance. The performance of postmenopausal women not taking MHT was similar to
that of premenopausal women. There were no menopausal transition effects on working
memory. The disturbance in cognitive performance during perimenopause was subtle,
and viewed as lack of improvement over time rather than overt decline. Return to
premenopausal levels of performance in the postmenopause period suggests that
cognitive difficulties during the menopause transition are transient. This is the first large,
longitudinal study where objective verbal memory test findings are consistent with
women‟s perceived memory problems during the menopausal transition. In contrast to the
results from the Chicago cohort of the SWAN study reported above (Meyer et al., 2003),
this study showed effects of the menopausal transition and hormone use on objective
cognitive testing (Greendale et al.). These newer results may differ because of the larger
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sample size, longer follow-up period and use of additional testing measures, as well as
documentation of previous and current hormone use.
Three longitudinal studies measuring women‟s memory performance during the
menopausal transition were examined (Fuh et al., 2006; Greendale et al., 2009; Meyer et
al., 2003), with others being cross-sectional. Findings in cross-sectional studies do not
differentiate between the possibility of a lower cognitive baseline rather than cognitive
decline. Studies measured different aspects of memory, or may have assessed similar
memory functions with different tests. With the exception of one prospective study
(Greendale et al., 2009), objective findings from neurocognitive testing do not provide
strong evidence for midlife cognitive changes during the menopausal transition with
respect to episodic verbal memory. Repeated neuropsychological testing required in
prospective studies results in significant practice effects on these tests, particularly in
midlife women, decreasing the likelihood of observing change in cognition and requiring
large sample sizes to have adequate power (Maki, 2004; Maki et al., 2010). Three crosssectional studies found associations between memory complaints and tests of attention
(Schaafsma, Homewood, & Taylor, 2010; Weber & Mapstone, 2009; Weber et al., 2012)
which suggests that aspects of cognition aside from episodic verbal memory may play a
role in reduced performance in midlife women.

Menopausal Symptoms in Breast Cancer Survivors
Ganz and colleagues (1996) surveyed breast cancer survivors (xˉ age = 58) at 2
years (n = 69) and 3 years (n = 70) after initial surgery who had been assessed at four
time points during the first year following treatment. Overall, outcomes on general
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measures of health and well being suggested that these women were functioning at a high
level compared to patients with other chronic diseases. In spite of these findings, women
identified a number of physical and psychosocial problems that persisted or worsened
over time. Although not rated as severe in intensity, approximately 50% of each group
self reported difficulty remembering, and one-third of the 2-year group and one quarter of
the 3-year group self reported that they had difficulty concentrating and thinking clearly.
In a longitudinal study of quality of life (QOL) in long-term, disease-free breast
cancer survivors, 763 women (xˉ age = 55.6) were surveyed between 5 and 10 years (xˉ
years = 6.3) after diagnosis (Ganz et al., 2002). Considerable stability in health-related
QOL was observed since the time of a previous survey (mean time since diagnosis at
initial evaluation = 3.4 years) with modest declines in physical functioning that reflected
expected age-related changes. A significant increase from baseline was seen in selfreported forgetfulness (p = .001), difficulty concentrating (p = .047), and being easily
distracted (p = .014), with a significant decline reported in the frequency of hot flashes
(HF) (p = .001) and night sweats (p = .001). Women without past systemic adjuvant
therapy (chemotherapy, tamoxifen, or both) had a better global QOL than those who had
received systemic adjuvant therapy (p = .005).
Using the Breast Cancer Prevention Trial Symptom Checklist, Crandall and
associates (2004) surveyed 476 women (xˉ age = 50) enrolled in a cohort study of breast
cancer survivors diagnosed before age 50. An average of six years had elapsed since
diagnosis. Menopausal status was classified as premenopausal (13%), perimenopausal
(16%), and postmenopausal (71%). Forgetfulness and difficulty concentrating did not
differ in prevalence or severity with menopausal status. After adjusting for a number of
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core variables in logistic and linear regression models including age, years since
diagnosis, type of breast cancer treatment and whether a menopause transition was
experienced in relation to breast cancer treatment, peri- and postmenopausal women were
no more likely to report these memory symptoms than were premenopausal women, nor
were the memory symptoms more severe. Having experienced a menopausal transition
after breast cancer therapy did not significantly increase the prevalence or severity of
memory outcomes in peri- and postmenopausal women. A statistically significant
difference was shown in the prevalence (p < .0001) and severity (p < .0001) of HF across
menopausal status categories, with an increasing trend with advancing stages of the
transition. Perimenopausal (OR 4.40, 95% CI 1.83-10.56) and postmenopausal women
(OR 9.09, 95% CI 3.73-22.14) were significantly more likely to report HF compared with
premenopausal women, with the HF also being more severe (p = .02; p = .0001,
respectively). Peri- and postmenopausal women with a treatment-related menopausal
transition had a greater severity of current HF than those in the same menopausal status
groups without a treatment-related transition (p = .03). Controlling for the additional
variable of current tamoxifen therapy, in addition to the core variables, did not change the
relationship between menopause status and severity of HF.
Carpenter and Andrykowski (1999) conducted telephone interviews of 114
postmenopausal breast cancer survivors (xˉ age = 58.8) about their menopausal symptoms
and QOL. These women had a mean time from last menstrual period of 12 years, and
34.9 months from completion of treatment. Forty-nine percent of the women were pre- or
perimenopausal at diagnosis. Overall, the most commonly reported menopausal
symptoms (joint pain, feeling tired, trouble sleeping, HF/night sweats) were also the most
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severe. The total number and severity of symptoms were significantly related to years
postmenopause (r = -0.30, p = .001), with more symptoms and higher severity reported
by women with fewer years since last menstrual period. The total number and severity of
symptoms were not related to time since diagnosis. Memory changes were not addressed
in this study.
In a cross-sectional study of 132 women, Carpenter and colleagues (2002)
compared the experience of HF in 69 breast cancer survivors (xˉ age = 57.2) to 63 agematched healthy volunteers (xˉ age = 55.7). Breast cancer survivors were at least three
months post completion of surgery, radiation, or chemotherapy, and a mean of 39 months
post diagnosis. Significantly more survivors reported daily HF (65%) compared to
healthy women (16%). HF severity (p = .001) and bother (p = .001) were significantly
higher among breast cancer survivors in comparison to healthy women. Survivors also
reported more frequent and severe HF with greater duration compared to healthy women.
The quality of the HF, determined by descriptive phrases from the HF questionnaire (e.g.,
perspiring, anxious, embarrassed), was similar between groups. Differences in HF were
also analyzed using a subset of women who were naturally menopausal, with 22 breast
cancer survivors versus 35 healthy women. For naturally postmenopausal breast cancer
survivors, HF were significantly more severe (p = .027), bothersome (p = .031), and of
greater duration (p = .003) in comparison to naturally postmenopausal healthy women.
Survivors reporting HF had a significantly greater interference with daily activities and
overall QOL (p < .01), and those with daily HF reported moderate to severe interference
with concentration. The mean number of treatments used to alleviate HF by breast cancer
survivors was not significantly different from healthy women. Use of two types of HF
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treatments differed significantly between groups; MHT was used by fewer breast cancer
survivors, and more survivors had tried nonhormonal prescription medications. Despite
similarities in types and numbers of treatments used, breast cancer survivors reported
their current HF treatments to be significantly less effective (p < .05) than did healthy
women.
A pooled analysis combining baseline symptom data from three independent
studies of women with breast cancer was done to describe symptom prevalence
attributable to breast cancer, and clusters of symptoms across three phases of the disease
(Bender, Ergun, Rosenzweig, Cohen, & Sereika, 2005). The three studies included (a)
women with early-stage breast cancer post surgery but prior to adjuvant therapy, (b)
women with early-stage disease following adjuvant therapy, and (c) women with
metastatic disease receiving palliative treatment. A panel of oncology nursing experts
determined 13 measured items that were common to all three studies for analysis. Each
identified cluster was comprised of symptoms of fatigue, perceived cognitive impairment,
and mood problems, with descriptors of each symptom included for the specific study
group. This unique symptom cluster may exist across these three phases of the breast
cancer disease sequence.
Young mid-life women with breast cancer (n = 27, xˉ age = 40.8) who experienced
chemically-induced premature menopause participated in a qualitative study exploring
their responses to menopausal symptoms (Knobf, 2001). Mean time since diagnosis was
4.5 years. Changes in menstrual cycle function, HF, and cognition were among those felt
to be associated with chemotherapy-induced menopause. Cognitive complaints were
commonly described as difficulty concentrating and forgetfulness. Distress associated
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with these complaints varied according to their effect on daily functioning at home or at
work. HF were common and persistent symptoms, lasting for years following therapy,
and became a more dominant concern after chemotherapy was completed. The severity of
HF was not quantified, but distress varied considerably from mild to very bothersome. In
another analysis of this group of women, Knobf (2002) reported those who experienced
more severe physical symptom distress actively searched for symptom relief measures.
Many of these studies assessed menopausal symptoms at a single point in time,
and demonstrate that breast cancer survivors who are several years post diagnosis
experience a variety of symptoms, including HF and memory changes. Survivors
described HF as severe compared to healthy women. HF varied in prevalence and
severity with menopausal status and the occurrence of a menopausal transition related to
treatment.

Menopausal Symptoms and Memory
It has been suggested that HF may be linked to other menopausal symptoms in a
cascade of events where HF disturb sleep, leading to irritability, fatigue and memory
disturbances (Kronenberg, 1990). Studies examining the relationship between
menopausal symptoms and cognition have not found a significant association between
subjective reports of HF and verbal memory measures. However, a recent study found
that objectively measured HF, compared to self-reported HF, were a significant predictor
of poorer verbal memory performance (Maki et al., 2008). Interestingly, several studies
of women with HF have found that self-reported HF counts greatly underestimate the
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number of objectively recorded HF (Carpenter, Monahan, & Azzouz, 2004; Freedman &
Wasson, 2007; Maki et al., 2008; Sievert et al., 2002).
A multicenter pilot study enrolled 180 healthy, naturally postmenopausal women
with subjective cognitive complaints aged 45 to 55 years, whose last menses had been
completed ≥ 12 and ≤ 36 months prior to study screening (Maki, Gast, Vieweg, Burriss,
& Yaffi, 2007). The women were randomly assigned to receive either placebo or
conjugated equine estrogen with medroxyprogesterone acetate (MHT group) for four
months. Memory (specifically verbal memory and learning) and self-perception of
memory function were measured at baseline and at month four. Vasomotor symptoms
(hot flashes) were self reported. Analysis of covariance was used to assess changes from
baseline. MHT use was associated with improvement in both frequency and severity of
hot flashes compared with baseline and placebo. Total scores on the verbal learning test
were decreased in both MHT and placebo groups, with no difference between groups.
Short- and long-delay free recall subscores decreased in the MHT group which
approached significance (p = .054; p = .066, respectively). This finding of nearsignificant, modest negative effects of combined estrogen and progestin therapy,
specifically the commonly prescribed hormone preparation used in this study (Maki &
Sundermann, 2009), contrasts with findings of earlier studies using estrogen alone
(Phillips & Sherwin, 1992; Shaywitz et al., 2003; Sherwin, 1988). Scores on the Memory
Functioning Questionnaire showed significant improvement from baseline in selfreported seriousness of forgetting in the MHT group (p = .028), but no difference was
seen between groups in any measure of the questionnaire at month four. Post hoc
analyses were conducted according to presence or absence of HF at baseline. No
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differences that had not been seen previously in tests of attention, memory or cognition
were detected. In this study, MHT was not associated with improved cognitive function
vs. placebo.
In a two-part study, LeBlanc and associates (2007) examined the effects of
menopausal symptoms and symptom relief with estrogen therapy (ET) on cognition in
early menopause. In the cross-sectional component, 37 women (xˉ age = 53) completed
symptom questionnaires, HF diaries and sleep journals for one week prior to cognitive
testing. They were then divided into high symptom (n = 17) and low symptom (n = 20)
groups. Cognitive measures included assessment of verbal memory using immediate and
delayed paragraph recall. In this part of the study, menopausal symptom status was not
related to cognition, with women in both groups performing similarly on all measures of
cognitive performance. Thirty-two of the women then completed the treatment study with
either ET or placebo for eight weeks, with repeat cognitive testing at four and eight
weeks. According to self reports, the ET group had significant symptom relief (p = .03),
significantly fewer HF (p = .02), and significant improvement in sleep quality (p = .05)
than those taking placebo. Women taking ET did not perform better on any of the
cognitive measures than those on placebo. Symptom status did not interact with effects of
ET on cognition. Because of short test-retest periods of cognitive function (three times in
an 8-week period), practice effects may lessen the possibility of measuring a significant
hormone effect in this small sample.
Fifty peri- and recently postmenopausal women were randomly assigned to ET (n
= 26, xˉ age = 50.8) or placebo (n = 24, xˉ age = 51.3) groups in a study examining
estrogen‟s influence on specific cognitive processes, and whether its effect is moderated
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by HF and sleep (Joffe et al., 2006). A neurocognitive test battery, including measures of
verbal memory, was administered at baseline and at the end of 12 weeks of treatment,
along with subjective measures of HF and sleep. Prior to treatment, HF were reported by
57.7% and 66.7 % of women randomized to ET and placebo respectively. At study end,
HF improved in both groups, with a significant improvement in HF from baseline in
estrogen-treated women compared with the placebo group (p = .01). Comparison of
groups using linear regression showed that while there were few differences between
groups in performance on cognitive tasks, women in the ET group had significantly fewer
perseverative errors during verbal recall (p = .03), and a trend toward less interference
during verbal recall (p = .07). These are measures of executive function rather than verbal
memory itself; executive functions are processes mediated by the prefrontal cortex that
assist in encoding and retrieval in memory tasks (Maki & Sundermann, 2009). Sleep
quality improved in both groups, with no group differences seen. Sleep quality at baseline
and at study end did not correlate with change in verbal recall errors or cognitive
performance in the women as a whole, or between ET and placebo groups. In this study,
improvement in measures of cognitive function (specifically that of attention) in the ET
group correlated with improvement in HF but not with sleep quality.
Maki and colleagues (2008) investigated the relationship between objectively
measured HF and the primary cognitive outcome measure of verbal episodic memory in a
sample of 29 women (xˉ age = 53.1) with moderate to severe HF. An ambulatory sternal
skin conductance monitor was used to measure HF. Tests of immediate and delayed
paragraph recall measured verbal memory. There was an underreporting of objective HF
by 43% in a 24-hour period; daytime HF were underreported by 40%, and nighttime HF
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by 60%. The total number of objective HF over a 24-hour period showed a significant
negative correlation with delayed paragraph recall ( r = -0.40, p < .05) and showed a
negative trend for immediate paragraph recall (i.e., the greater the number of objective
HF measured in a 24-hour period, the poorer the performance on the paragraph recall
test). The number of objective HF while awake did not correlate with immediate or
delayed paragraph recall. Total number of objective HF during sleep had a significant
negative relationship with both immediate paragraph recall (r = -0.43, p < .05) and
delayed paragraph recall (r = -0.48, p < .01), even when controlling for sleep duration.
Shorter sleep duration had a significant negative relationship with immediate paragraph
recall (r = -0.41, p < .05). Sleep duration and nighttime HF contributed independently to
impaired verbal memory; this suggested to the researchers that the influence of HF on
other menopausal symptoms may not be related to sleep disruption. Subjective HF did
not correlate significantly with verbal memory performance, which is consistent with
previous studies (Joffe et al., 2006; LeBlanc et al., 2007; Maki et al., 2007).
In these studies, the inconsistency seen in the relationship of menopausal HF to
memory changes may be attributed to a number of methodological issues that should be
considered when interpreting the findings. The studies differed in their design and
methodology, including sample size, age of subjects, cross-sectional vs. longitudinal
design, use of different hormone preparations and neurocognitive tests, and subjective vs.
objective reporting of memory and vasomotor symptoms. In addition, practice effects
occurring with repeated neuropsychological testing may have obscured treatment effects.
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Memory in Breast Cancer Survivors
Chemically induced menopause is the permanent, premature suppression of
ovarian function in response to chemotherapeutic agents. The incidence of menopause
varies with different types and doses of chemotherapy, with risk increasing with age
(Anders, Johnson, Litton, Phillips, & Bleyer, 2009). The risk of menopause with multiagent adjuvant chemotherapy for breast cancer can range from 21-71% in younger
premenopausal women, to 49-100% in women older than 40 years (Bines, Oleske, &
Cobleigh, 1996; Fornier, Modi, Panageas, Norton, & Hudis, 2005; Pérez-Fidalgo et al.,
2010; Petrek et al., 2006). For women with breast cancer, adjuvant hormone (or
endocrine) therapy refers to treatment with a selective estrogen receptor modulator,
usually tamoxifen, or an aromatase inhibitor, such as anastrozole.
In a cross-sectional study, van Dam and colleagues (1998) investigated the effect
of high-dose vs. standard-dose chemotherapy on cognitive functioning in breast cancer
survivors who had previously undergone surgery. The sample consisted of 34 women
treated with high-dose chemotherapy plus tamoxifen (Group 1, xˉ age = 45.5), 36 women
treated with standard-dose chemotherapy plus tamoxifen (Group 2, xˉ age = 48.1), and 34
women as controls with stage I breast cancer who had received no adjuvant therapy
(Group 3, xˉ age = 46.1). The women in the chemotherapy groups had stage II and III
breast cancer, and had finished chemotherapy an average of 2 years earlier. Thirteen of
these women had already completed tamoxifen therapy. All women in Group 1 were
postmenopausal due to chemotherapy. Two women in Group 2 and 21 women in Group 3
were premenopausal, with the remainder of women in those groups postmenopausal.
Women were interviewed about their cognitive problems in daily life, and a
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neuropsychological test battery was administered. The two chemotherapy groups
expressed significantly more problems with concentration (p = .006), memory (p = .006),
and thinking (p = .022) than those in Group 3, with no significant difference between
Groups 1 and 2. The scores on neuropsychologic tests were not significantly different
between Groups 1 and 2. Group 1 scored significantly lower than Group 3 on seven of
the 21 test indices (p < .05). Subjects were classified as cognitively impaired when
scoring two standard deviations (SD) below the mean of the controls on three or more
neuropsychologic tests (32% high dose; 17% standard dose; 9% no chemotherapy). Risk
of cognitive impairment was calculated using a logistic regression model, and was high
for Group 1 compared with Group 3 (p = .006), with a trend toward significance when
compared with Group 2 (p = .056). The risk of cognitive impairment for Group 2 was
elevated in comparison with Group 3, but was not significant. Test results of the pre- and
postmenopausal women in Group 3 did not differ. The researchers concluded that highdose chemotherapy seems to impair cognitive function more than standard dose
chemotherapy.
Thirty-nine women with breast cancer who had completed CMF chemotherapy
(cyclophosphamide, methotrexate, and 5-fluorouracil) at least six months earlier, and a
control group with breast cancer not treated with chemotherapy (n = 34) were examined
for cognitive deficits related to treatment (Schagen et al., 1999). The groups were
matched for age and time since treatment. Twenty of the women in the first group had
their chemotherapy followed with tamoxifen. Subjects were given a neuropsychologic
test battery and interviewed for perceived cognitive functioning, similar to an earlier
study (van Dam et al., 1998). Three women in the chemotherapy group were
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postmenopausal prior to diagnosis, and all other women in that group experienced a
menopausal transition related to treatment. In the control group, 13 were postmenopausal
and 21 were premenopausal. Results were compared for the pre- and postmenopausal
controls with no differences observed. There were no differences between women treated
with chemotherapy with tamoxifen and those treated with chemotherapy alone on any
outcome measure, so these women were analyzed together as one group. Women in the
chemotherapy group identified problems with concentration (31 % vs. 6%, p = .007) and
memory (21% vs. 3%, p = .022) at significantly higher rates than the control group. The
chemotherapy group had significant differences on 12 of 21 neuropsychologic test
indices (p < .05), with worse performance than the control group on visual memory,
verbal and motor function, delayed recall (verbal memory), reaction time (speed of
information processing), and some measures of mental flexibility and attention. Cognitive
impairment was determined using the same method as an earlier study (van Dam et al.,
1998). Classification of cognitive impairment was 28% in the chemotherapy group and
12% in the control group. The risk of cognitive impairment was highly increased for
women treated with chemotherapy compared with the control group (p = .013).
Schagen and colleagues (2002) reevaluated the cognitive status of all patients
remaining disease free who had participated in two previous neuropsychological studies
(Schagen et al., 1999; van Dam et al., 1998). In the initial cross-sectional studies (T1),
testing was conducted two years post-therapy on average. In this study (T 2),
approximately four years following therapy, the same assessment measures were used.
At T2, there were 22 of 34 original participants in the high-dose chemotherapy group, 23
of 36 in the standard-dose group, 31 of 39 in the CMF group, and 27 of 34 in the non-
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systemically treated control group. Improvement in performance was seen in all
chemotherapy groups, with a slight, though not significant, deterioration on testing in the
control group. No differences in test outcomes were found in the chemotherapy groups
between women who had completed, were still taking, or who had never used tamoxifen.
None of the previously observed differences in cognitive functioning between
chemotherapy and control groups was demonstrated at T2. Interpretation of these findings
is limited by differential attrition among the groups due to factors related to disease
progression, particularly of women who were classified as cognitively impaired at T1.
Wieneke and Dienst (1995) administered a battery of neuropsychological tests to
28 women (xˉ age = 42) with stage I or II breast cancer who had completed standard-dose
chemotherapy an average of 6.6 ± 4 months earlier (range 0.5-12 months). Eleven women
were taking tamoxifen at the time of testing. Menopausal status was not noted. Scores
were compared with published test norms of healthy matched controls. Multivariate
analyses of variance showed significant decreases in the areas of visual and verbal
memory, mental flexibility and processing speed, attention and concentration,
visuospatial ability, and motor function. Seventy-five percent of women scored in the
range of moderate impairment, which was defined as scoring more than 2 SD below the
mean score on at least one neuropsychological measure. Treatment duration, but not type
of treatment, time since treatment or tamoxifen therapy, was significantly related to
impairment (r = 0.39, p < .01).
Donovan and colleagues (2005) recruited women diagnosed with stage 0 – II
breast cancer who had received chemotherapy and radiotherapy (n = 60, xˉ age = 52.3) or
who had received radiotherapy but not chemotherapy (n = 83, xˉ age = 57.6). The
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radiotherapy only group was significantly older, had more postmenopausal women, and
more women were taking hormone therapy. Menopausal status was assessed only prior to
treatment. A neuropsychological test battery and self-report measure of cognitive
problems were administered 6 months following completion of treatment. There were no
significant group differences on neuropsychologic test scores, prevalence of cognitive
impairment (which was low), or scores of cognitive complaints, though both groups
reported that they frequently experienced cognitive problems.
Breast cancer survivors (n = 53) with stage 0 – II breast cancer who were 2 to 5
years from diagnosis and a group of healthy controls without cancer (n = 19, xˉ age =
49.2) were enrolled in a study to evaluate the impact of chemotherapy on cognitive
function (Castellon et al., 2004). The survivors were divided into treatment groups of
chemotherapy (n = 36, xˉ age = 46.8), and no chemotherapy (n = 17, xˉ age = 48.3). Half
of the women in the chemotherapy group also received tamoxifen. Menopausal status
was not noted. A neurocognitive test battery and self-report questionnaire of cognitive
function were administered. Multivariate analysis of variance of cognitive test scores
showed that women exposed to chemotherapy scored significantly lower than cancer
survivors with no chemotherapy in visuospatial (p = .005), visual memory (p = .01), and
verbal learning (p = .03) domains. In an exploratory analysis, women who received both
chemotherapy and tamoxifen showed a greater risk of cognitive compromise, having the
lowest group means on five of eight cognitive domains. Breast cancer survivors without
chemotherapy performed similarly to the healthy controls. The authors noted that overall
cognitive compromise in the chemotherapy group was fairly mild in nature.
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A prospective, longitudinal study incorporating neuropsychologic testing prior to
treatment was designed to evaluate cognitive sequelae in women with breast cancer
treated with chemotherapy (Wefel, Lenzi, Theriault, Davis, & Meyers, 2004). Women
diagnosed with stage I – III breast cancer (n = 18, xˉ age = 45.4) were evaluated with a
cognitive test battery following surgery, and before the start of chemotherapy (T 1,
baseline); approximately six months after baseline, and at least 3 weeks after cessation of
drug treatment (T2); and one year post-chemotherapy, about 18 months after baseline
(T3). Menopausal status was noted only at baseline: premenopausal (n = 9),
perimenopausal (n = 1), postmenopausal (n = 8). At baseline, 33% of the women were
classified as having cognitive impairment. At T 2, 61% of the group exhibited decline
from baseline in one or more cognitive domains, most commonly those related to
attention, learning, and processing speed. At T3, 45% who had experienced decline from
T1 to T2 showed improvement, 45% remained stable, and 10% had improved on some
measures and remained stable on others. The patient cohort as a whole did not show a
statistically significant decline in cognitive function from baseline to T 2, or from T2 to T3,
though a subset of women did demonstrate a decline following chemotherapy. Declines
seen were subtle, and performance results often fell within the average range when
compared with results of similar healthy control individuals.
Ahles and colleagues (2008) examined neuropsychological functioning of women
following surgery for breast cancer prior to starting chemotherapy, radiation, or hormonal
therapy. Women (Group 1) with stage I – III breast cancer (n = 110, xˉ age = 54.1),
women (Group 2) diagnosed with stage 0 breast cancer (n = 22, xˉ age = 55.8), and
healthy controls (n = 45, xˉ age = 52.9) completed a neuropsychological test battery. All
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groups‟ scores on neuropsychological tests were within the normal range. Using chisquare tests to examine group differences, the researchers found Group 1 was
significantly more likely (p = .002) to be classified as having lower than expected rate of
overall cognitive performance (22%) as compared to Group 2 (0%) and healthy controls
(4%). The areas contributing to this classification were verbal fluency, mental flexibility,
and visual, verbal and working memory.
In a prospective study, Bender and associates (2006) examined three groups of
pre- and perimenopausal women with breast cancer for cognitive changes related to
therapy over time. Two groups consisted of women with stage I or II breast cancer:
Group 1 (n = 19, xˉ age = 40.1) received chemotherapy alone, and Group 2 (n = 15, xˉ age
= 44.1) received chemotherapy and tamoxifen. Group 3 (n = 12, xˉ age = 44.5) consisted
of women with breast cancer who received no chemotherapy or tamoxifen.
Measurements included a neuropsychological test battery and self-report of cognitive
function. These were administered after surgery and before treatment, if applicable (T 1);
one week following completion of chemotherapy, and at a comparable time for Group 3
(T2); and at Time 3 (T3), one year following T2. No significant differences were seen
between groups on any memory measure at baseline (T 1). Women receiving
chemotherapy and tamoxifen showed poorer performance on measures of visual and
verbal working memory, while women receiving chemotherapy alone exhibited poorer
performance in verbal working memory. Most of these changes were seen at T 3, when
women in Group 2 were still receiving tamoxifen. Scores for women with no treatment
showed improvement from T2 to T3, which may be indicative of practice effects. The
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researchers suggest that cognitive problems experienced by breast cancer survivors
treated with adjuvant therapy are subtle and domain specific.
A cross-sectional study was conducted to compare cognitive abilities of tamoxifen
users with healthy controls (Palmer, Trotter, Joy, & Carlson, 2008). The tamoxifen group
consisted of women treated for breast cancer with surgery and/or radiation without
chemotherapy (n = 23, xˉ age = 45.8) who had been taking tamoxifen for an average of
2.3 years. The healthy control group (n = 23, xˉ age = 45.3) had no cancer history. All
women were premenopausal. On a neuropsychological test battery, scores were compared
using t tests, with the tamoxifen group having significantly worse scores than the control
group on visual memory, word fluency, processing speed, visuospatial ability, and
immediate verbal memory tasks. Taking into consideration the study design and small
sample size, the authors suggest that tamoxifen use in premenopausal women with breast
cancer may be associated with cognitive difficulties.
A number of studies examining cognition in women treated for breast cancer have
included women taking hormone therapy, with several studies combining users of
tamoxifen and aromatase inhibitors in the same group (Collins, Mackenzie, Stewart,
Bielajew, & Verma, 2009a; Jenkins, Shilling, Fallowfield, Howell, & Hutton, 2004;
Stewart et al., 2008). Women receiving hormone therapy in these studies had never been
treated with chemotherapy.
In a cross-sectional study (Jenkins et al., 2004), postmenopausal women with
breast cancer taking hormone therapy for an average of 36 months (n = 94, xˉ age = 63.1)
were compared to a control group of healthy postmenopausal women (n = 35, xˉ age =
60.9) on a battery of neuropsychological measures. Univariate analysis of variance
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showed a significant group difference on the tasks of processing speed (F = 3.966, p =
.049) and immediate verbal memory (F = 4.578, p = .034), with the hormone therapy
group demonstrating poorer performance.
Stewart et al. (2008) compared performance on cognitive tests in postmenopausal
women with breast cancer who were scheduled to receive chemotherapy (n = 61) or
hormone therapy (n = 51) at baseline (T 1) prior to any treatment, and at completion of
chemotherapy (T2) with a comparable assessment time for the hormone group. Cognitive
change was calculated using a standardized regression-based score involving prediction
of retest scores using the baseline scores for each neuropsychological test. A subject
showed cognitive decline if scoring 2 or more SD below the predicted score on two or
more tests. At T2, the chemotherapy group showed a significantly higher rate of cognitive
decline (χ2 = 6.02, p = .014) than the hormone group (31% and 12%, respectively), with a
significant decrease in the working memory domain (t = -2.0, p = .05). However, mean
scores of both groups were within the normal range of published scores at both time
points.
A longitudinal study (Collins et al., 2009a) compared hormone therapy users (n =
40) to a chemotherapy group (n = 53) at baseline prior to therapy (T1); one month after
completion of chemotherapy, approximately 6 months from baseline (T 2); and one year
after the second assessment (T3). All women were postmenopausal at baseline. In the
chemotherapy group, 17% and 72% were taking hormone therapy at T2 and T3
respectively. Calculation of cognitive decline was conducted in the same manner as in an
earlier study (Stewart et al., 2008). At T2, the chemotherapy group showed a significantly
higher rate of cognitive decline (χ2 = 5.64, p = .02) than the hormone group (34% and
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12% respectively), with working and visual memory most affected. At T 3, the
chemotherapy and hormone groups did not differ in rate of cognitive decline, but the
chemotherapy group scored significantly better in the area of executive function (t = 2.94,
p = .004). The women in the chemotherapy group taking hormonal therapy at T 3 had
significantly lower scores on processing speed (t = 2.89, p = .01) and verbal memory (t =
2.71, p = .01) than women in the chemotherapy group not taking hormonal therapy. The
results of this study are in keeping with other longitudinal studies which indicate that
cognitive changes emerge during or shortly after chemotherapy and suggest that they may
resolve over time (Schagen et al., 2002; Wefel et al., 2004).
Other studies have evaluated the cognitive effects of hormonal therapy in women
with breast cancer, comparing tamoxifen to aromatase inhibitors (Bender et al., 2007;
Collins, Mackenzie, Stewart, Bielajew, & Verma, 2009b; Schilder et al., 2009). In a
cross-sectional study, Bender and colleagues (2007) examined cognitive function in
postmenopausal women with early stage breast cancer receiving tamoxifen (n = 16, xˉ age
= 48.2) and those receiving the aromatase inhibitor anastrozole (n = 15, xˉ age = 57.4).
Women in the anastrozole group were significantly older, and women taking tamoxifen
had been receiving that therapy for a significantly longer period of time. There was no
difference between groups in the number of women who had been treated with
chemotherapy prior to hormone therapy. Women receiving anastrozole had significantly
worse performance on visual and verbal learning and memory measures than women
receiving tamoxifen. After controlling for the covariates of age, therapy duration, years of
education, fatigue, anxiety, and depression, impairments in visual and verbal learning and
memory domains remained significant for women receiving anastrozole.
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Schilder at al. (2009) compared two groups of women with breast cancer taking
hormone therapy two years following completion of chemotherapy with a group of
healthy postmenopausal controls (Group 3; n = 48). Group 1 (n = 30) was taking
tamoxifen, and Group 2 (n = 50) received exemestane, an aromatase inhibitor. Using
multivariate analysis of variance, the researchers found no significant difference between
Groups 1 and 2 on overall cognitive functioning. Worse overall cognitive functioning
was seen between Groups 1 and 2 combined and Group 3 (F = 2.8, p = .001). Both
hormone therapy groups performed significantly worse than Group 3 on verbal fluency
and processing speed measures. Groups 1 and 2 combined reported significantly more hot
flashes and night sweats (p = .001) than Group 3.
Two groups of postmenopausal women with breast cancer who had never
received chemotherapy were treated with tamoxifen (n = 31) or anastrozole (n = 14)
(Collins et al., 2009b). A group of healthy postmenopausal women (n = 28) served as
controls. Neuropsychological testing was done at baseline (T 1) close to initiation of
hormone therapy, and repeated 5-6 months later (T2). Measurement of cognitive decline
was performed as in earlier studies by the authors (Collins et al., 2009a; Stewart et al.,
2008). Cognitive decline from T1 to T2 was seen in all groups (tamoxifen 39%,
anastrozole 64%, and controls 7%). The decline in the tamoxifen (χ2 = 8.10, p = .00) and
anastrozole (χ2 = 15.77, p = .00) groups was significantly different compared to the
healthy controls, but did not differ between treatment groups. With covariates of age and
education, analysis of covariance showed processing speed (p = .02), verbal memory (p =
.03), and overall cognitive summary scores (p = .02) were significantly different between
the anastrozole and healthy groups, with the anastrozole group scoring lower. Processing
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speed was also significantly lower in the tamoxifen group (p = .02) compared with
healthy controls. The researchers concluded that cognitive changes were subtle in this
study, as mean raw scores on cognitive measures in the hormonal groups fell within the
range of published norms at both T1 and T2.
A group of studies on cognitive functioning in breast cancer survivors who
received adjuvant therapy demonstrate that a subset of these women show deficits on
neurocognitive testing. However, many studies looking at cognition in breast cancer
survivors differ in their findings, and have considerable variability in subjects studied
(e.g., age, type and dose of chemotherapeutic regimens, use and type of hormonal
treatment, time since treatment), as well as in study design and methodology which limit
comparability of results. Most studies are cross-sectional, and use different time points of
assessment, small sample sizes, varying or no control groups, and different measures of
cognitive function. Criteria used to classify cognitive decline or impairment vary. The
cognitive domains affected by adjuvant therapy exposure are not consistent across
studies, but deficits are frequently seen in memory, learning, attention, processing speed
and executive function. Most studies do not address the possible interaction of adjuvant
therapy and menopausal status, or change in menopausal status, during treatment on
memory. Cognitive impairment may predate adjuvant therapy in some women, and not
all studies include pre-treatment evaluation of cognitive function. Cognitive effects of
chemotherapy and hormonal therapy may be subtle and difficult to detect. Several studies
found that women‟s self-reported cognitive complaints are not reflected on objective
testing (Bender et al., 2006; Castellon et al., 2004; Donovan et al., 2005). This
phenomenon, also seen in studies of healthy midlife women, may be attributed to the lack
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of sensitivity of neuropsychological measures used, cross-sectional study design, or lack
of consideration of other contributing factors that may influence cognition, such as
menopausal status.

Acupuncture
Acupuncture is a widely used therapeutic modality which has been proposed as a
treatment for menopausal symptoms. Several randomized controlled trials have examined
the effectiveness of acupuncture (AP) as a treatment option for menopausal symptoms, in
both naturally menopausal women and breast cancer survivors.
Acupuncture and menopausal symptoms. Vincent and colleagues (2007)
recruited 103 peri- and postmenopausal women aged 45-59 with ≥ five HF per day who
were randomized to medical or sham AP groups. Sham AP was defined as needling in
nonacupuncture, nonmeridian areas. Ten AP treatments were administered twice weekly
for five weeks. Mean daily HF scores (frequency x severity) were calculated for each
participant from HF diaries. HF scores decreased from baseline in both groups at end of
treatment and at follow-up in seven weeks. There was no significant difference between
the two groups. Results did not show that the medical AP was more effective than the
sham AP therapy used in this study.
Nir et al. (2007) studied 29 postmenopausal women (xˉ age = 55) with ≥ 7
moderate to severe HF per day who were randomly assigned to active or placebo AP
groups. Following treatment principles of traditional Chinese medicine (TCM), active AP
was tailored to individual clinical presentations according to a standardized algorithm.
Placebo AP was at nonvalid points off AP channels with no needle penetration. Nine AP
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treatments were administered: twice weekly for two weeks, then once a week for five
weeks with a one month follow-up period. HF scores were derived from daily logs.
Improvement in quality of life was measured by the Menopause-Specific Quality of Life
Questionnaire (MENQOL). Group differences in percent of change in severity and
frequency of HF were assessed using Mann-Whitney tests. Repeated measures analysis of
variance was used to calculate HF changes within groups. Both groups had significantly
decreased HF frequency from baseline (p ≤ .001), with no difference between groups.
There was a significant decrease in HF severity in the active AP group (p = .003), but not
for the placebo group, with a significant difference in HF severity between groups (p =
.042). HF severity and frequency remained lower in the active AP group than the placebo
group at the end of the follow-up period. No significant group differences were seen in
the four subscales of the MENQOL at any time point. Repeated measures analysis of
variance within groups showed a significant improvement in the vasomotor subscale for
both groups (p ≤ .001), but no significant improvement in the other subscales (one of
which contains a memory measure). These results show that standardized, individualized
AP was associated with a significantly greater decrease in severity, but not frequency, of
HF compared to placebo AP treatment of the same duration.
In a secondary analysis of the same group of 29 postmenopausal women and the
same treatment protocol used by Nir and colleagues (2007), Huang et al. (2006) assessed
the effectiveness of AP on nocturnal HF with similar results. Both groups demonstrated a
significant decrease in HF frequency (for both groups, p = .001), with no difference seen
between groups. A significant reduction from baseline in severity of nocturnal HF was
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seen with active AP (p = .002), with a significant difference between groups (p = .017) in
decreased severity of nocturnal HF with active AP.
Wyon and associates (1995) randomized 24 postmenopausal women with
vasomotor symptoms aged 47-62 to AP or control groups. The AP group received a
combination of electro-acupuncture and classical AP. The control group received
superficial needle insertion at the same points. Ten AP treatments were administered:
twice weekly for two weeks, then once a week for six weeks with a follow-up period of
three months. HF scores were based on daily HF logs. Symptoms were assessed using the
modified Kupperman Index. The symptoms on the Index not specified, but most likely
did not include a measure of memory. The Wilcoxon signed rank test was used for
pairwise comparisons within each group. HF frequency decreased significantly in both
groups from baseline through the treatment period (AP, p = .013; control, p = .0033) and
at three months after treatment (AP, p = .0033; control, p = .0069), with a trend toward
greater and longer lasting improvement seen in the AP group. A significant decrease on
the Kupperman Index was seen in both groups (p < .05), attributed mainly to scores for
vasomotor symptoms. No significant differences were seen between groups on any
measure at any time. Results did not show that active AP was more effective than the
control AP (superficial needling) used in this study.
Borud et al. (2009) recruited 267 postmenopausal women (xˉ age = 54) with ≥ 7
HF per 24 hours on 7 consecutive days with randomization to treatment or control
groups. The treatment group received advice on self care for menopausal symptoms in
the form of a one-page leaflet, as well as TCM acupuncture with point selection and
individualized treatment determined by the acupuncturist. Ten AP treatments were
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administered over 12 weeks. The control group received the self care advice leaflet. HF
scores were based on daily HF diaries. Health-related quality of life was measured by the
Women‟s Health Questionnaire (WHQ). Differences between groups were determined
with two-sample t tests. HF frequency (p < .001) and intensity (p < .001) decreased
significantly from baseline to 12 weeks in the AP group compared with the control group.
In this study, AP plus self care advice was more effective in reducing HF than self care
advice alone. Scores on the WHQ memory/concentration domain showed no statistically
significant difference in mean change from baseline to week 12 between the AP and
control groups. Significant difference was seen with improvement in the AP group in the
following WHQ domains: vasomotor (p < .001), sleep (p = .002), and somatic symptoms
(p = .01). Follow-up results at 6 and 12 months (Borud, Alraek, White, & Grimsgaard,
2010) showed that statistically significant differences between groups found at 12 weeks
were no longer evident.
Cohen and colleagues (2003) recruited 18 peri- and postmenopausal women (xˉ
age = 47.3) with self-identified menopausal HF who were randomized to experimental
AP or control AP groups. Experimental AP consisted of needling specific points related
to menopausal symptoms. The control group received AP treatment described as a
general tonic to benefit the flow of qi or vital energy. Six AP treatments were
administered: once weekly for three weeks, then once every other week for 3 weeks,
followed by a three week nontreatment period. HF data were gathered with daily
symptom diaries. Mean monthly HF severity decreased significantly in the experimental
AP group from baseline to month two (p = .05), baseline to month three (p = .005), and
baseline to month four (p = .019). No change was seen in the control group from baseline
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through the treatment phase. Between group comparisons were not done because of the
small sample size. Results suggest that menopause symptom-specific AP was effective in
reducing severity of HF during the treatment and follow-up periods.
Wyon et al. (2004) randomized 45 postmenopausal women with vasomotor
symptoms aged 48-63 to one of three groups. The AP group received electro-acupuncture
(EA). The control AP group received superficial needle insertion at different points from
EA group. Fourteen AP treatments were administered: twice weekly for two weeks, then
once a week for ten weeks. The estrogen group received 2 mg of oral estradiol daily for
12 weeks. All groups had a follow-up period of six months. HF scores were based on
daily HF logs. The modified Kupperman Index was used to assess symptom severity,
with no mention of a memory item on this version. HF frequency and severity decreased
significantly in all groups from baseline by 4 weeks (F(2,40) = 69.6, p < .001) and
remained unchanged through the follow-up period, though the effect of estrogen was
greater than that of EA. No significant difference was found between the acupuncture
groups over time. Findings were similar in the Kupperman Index scores, but the more
pronounced effect in the estrogen group was not seen at 24 weeks. Though estrogen was
more effective than AP, all three treatments were effective in decreasing HF frequency
and severity in this study.
Avis and associates (2008) recruited 56 peri- and postmenopausal women aged
44-55 with ≥ four moderate to severe HF per day who were randomized to one of three
groups. The AP group (n = 19) received TCM acupuncture using standardized treatment
plus additional needling based on individual diagnostic categories determined by the
acupuncturist. The sham AP group (n = 18) received superficial needling in

48

nontherapeutic sites believed to have a minimal effect on HF. Sixteen AP treatments were
administered twice weekly for eight weeks. The usual care group (n = 19) had a
scheduled clinic visit at four weeks and was instructed not to initiate any new HF
treatments. HF scores were calculated from daily HF diaries. A significant decrease was
seen in mean frequency of HF between treatment weeks one and eight across all groups
(p = .01). No significant differences in frequency were found between groups. When
combined, the two AP groups had a significantly greater decrease compared with the
usual care group (p < .05), but did not differ from each other. There was a significant
decrease (p = .02) over time in the HF index (a calculation involving frequency and
severity of HF) in both of the AP groups compared with the usual care group, with no
difference between the AP groups. Additional instruments were used to assess secondary
study outcomes of hot flash interference, sleep, mood, symptom bother, and healthrelated quality of life. These included the MENQOL and the Hot Flash Related Daily
Interference Scale, both of which contain a measure of memory. No significant results
were found for these outcomes other than the two AP groups reporting significantly less
vasomotor symptom bother (p < .02) than the usual care group. Results of this study
show that both standardized AP and sham AP were more effective than usual care in
reducing HF.
Zaborowska et al. (2007) recruited 102 postmenopausal women who requested
therapy for HF to two parallel studies. For Study I, 60 women were randomly assigned to
one of four groups, receiving either electro-acupuncture (EA), AP with superficial needle
insertion at different points from the EA group, applied relaxation, or oral estrogen
therapy (2 mg estradiol daily) for 12 weeks of treatment. Fourteen AP or EA treatments
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were administered: twice weekly for two weeks, then once a week for ten weeks. The
applied relaxation group met weekly for 12 weeks. For Study II, 42 women were
randomized to receive either a transdermal estrogen patch, or a placebo patch containing
no hormone. HF scores were based on daily HF logs for all women. A modified version
of the Kupperman Index assessed menopausal symptoms; it is not clear if a measure of
cognitive change was included. Statistics were calculated for all six groups. As the EA
and superficial AP groups did not differ from each other, they were analyzed together as
one AP group. The oral and transdermal estrogen groups also did not differ, and were
analyzed as one estrogen group. Changes in HF numbers were calculated using analysis
of variance and post-hoc Mann-Whitney tests. Daily HF frequency decreased from
baseline in all groups except placebo patch after 4 and 12 weeks. At 4 and 12 weeks, HF
were decreased significantly in the estrogen group (p < .01) compared with relaxation and
placebo patch, but not significantly more than AP. At 4 and 12 weeks, a significant
decrease in HF (p < .05; p < .01, respectively) was seen in the AP group compared with
placebo patch, and at 12 weeks (p < .05) in the relaxation group compared with placebo
patch. The Kupperman Index score did not change in the placebo group from baseline to
12 weeks. A decrease in scores differed significantly in all treatment groups from the
placebo group (p < .01), with no significant difference seen between the treatment
groups. Results indicate that AP and applied relaxation both reduced HF significantly
better than placebo. The researchers recommended further evaluation of AP and applied
relaxation as alternatives to MHT for menopausal vasomotor symptom relief.
Painovich and colleagues (2012) randomized 33 peri- and postmenopausal
women older that age 40 with at least 7 HF per day to traditional AP (n = 12), sham AP
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(n = 12), or waiting control (n = 9) groups. Sham AP consisted of AP without skin
penetration on non-active points. Three AP treatments per week were administered for 12
weeks. Frequency and severity of HF were recorded using a diary, and the MENQOL
was completed at study entry and exit to examine symptom impact on quality of life. At
the end of treatment, both AP groups showed reduction in HF frequency (≥ 86%) and
severity (≥ 78%) compared with the waiting control group, but were not statistically
different from each other. Comparison of means from the MENQOL using the Wilcoxon
rank sum test demonstrated significant improvement for both AP groups compared with
waiting control in the vasomotor domain (p = .01) and in the overall MENQOL score (p
= .03). In this study both traditional AP and sham AP were more effective than waiting
control in reducing HF.
Acupuncture in breast cancer survivors. Nedstrand and colleagues (2005)
evaluated the effectiveness of AP and applied relaxation on HF in women treated for
breast cancer. Thirty-eight women treated for breast cancer (xˉ age = 53) with moderate to
severe HF and either treatment-induced or spontaneous menopause were randomized to
groups receiving electro-acupuncture (EA) or applied relaxation. Fourteen EA treatments
were administered: twice weekly for two weeks, then once a week for ten weeks. The
applied relaxation group met weekly for 12 weeks, with a six month follow-up period for
both groups. HF frequency was derived from daily HF logs, and a modified Kupperman
Index provided menopausal symptom severity ratings. Memory was not assessed on this
version of the Kupperman Index. In the applied relaxation group, HF frequency and
symptom severity were significantly reduced from baseline starting at four weeks (p <
.001; p < .001, respectively) through the six month follow-up period (p < .0001; p < .001,
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respectively). HF frequency and severity of symptoms were also significantly reduced in
the EA group from baseline starting at four weeks (p < .001; p < .001, respectively)
through the six month follow-up period (p < .0001; p < .001, respectively). Between
group comparisons were not examined due to insufficient power.
Deng et al. (2007) recruited 72 women with breast cancer aged 48-59 with ≥ 3 HF
per day who were randomly assigned to true AP or sham AP groups. The true AP group
received needling using a 19- point prescription. Sham AP was without skin penetration
at points a few centimeters away from those used in the true AP group. Eight treatments
were administered twice a week for four weeks with follow-up at six weeks and six
months. Participants in the sham AP group were crossed over to eight sessions of true AP
starting at week 7. HF scores were based on diaries. Mean daily HF frequency decreased
from baseline in both groups at six weeks. HF reduction was greater in the true AP group,
but difference between groups was not significant. A further decrease in HF frequency
was seen in the sham AP group after cross-over to true AP at week 7. Reduction in HF
frequency was maintained at six month follow-up in both groups but was not
significantly different between groups.
Frisk and associates (2008) studied 45 women treated for breast cancer who
desired treatment for severe vasomotor symptoms, and randomized them to an electroacupuncture group (EA) or a menopausal hormone therapy (MHT) group (xˉ ages = 56.5
and 53.4 respectively). Fourteen EA treatments were administered: twice weekly for two
weeks, then once a week for ten weeks. The MHT group received a sequential or
continuous estrogen and progestin combination, or estrogen alone. The follow-up period
was 24 months. HF scores were derived from daily HF logs, with distress recorded on a
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range from 0 = no distress, to 10 = worst possible distress. A modified Kupperman Index
assessed menopausal symptoms, but did not include a memory measure. In both the EA
(n = 27) and MHT (n = 18) groups, frequency and degree of distress of HF were
significantly reduced at all measuring points over 24 months. In the EA group, HF
frequency and distress decreased significantly from start of treatment to 12 weeks (for
both frequency and distress, p < .001), start of treatment to 12 months (p = .003; p = .026,
respectively) , and start of treatment to 24 months (p = .003; p = .018, respectively). A
significant difference was seen between groups favoring decrease in frequency and
distress of HF in the MHT group at 12 months after start of treatment. Repeated measures
ANOVA analysis of the Kupperman Index symptom scores showed a significant
treatment effect over time for both groups, with a greater effect in the MHT group at 12
and 24 months (p = .002; p = .039, respectively). Further analysis of data from this study
(Frisk, Källström, Wall, Fredrikson, & Hammar, 2012) examined health-related quality
of life using the Women‟s Health Questionnaire (WHQ), which includes a
memory/concentration domain. The total WHQ score showed a significant decrease at all
time points in both groups, indicating improvement in symptoms, but no significant
difference in change was evident between groups. At least half of the EA group had a
clinically significant change of total WHQ after 12 weeks (the total length of EA
treatment) and at 12 months (58% and 50% of the group, respectively). In the MHT
group, 39% at 12 weeks, and 59% at 12 months experienced a clinically significant
change (MHT therapy was continuous). Anxiety, vasomotor symptom and sleep domain
scores on the WHQ, but not memory/concentration scores, improved significantly in the
EA group during the 24 month follow-up. In the MHT group, only vasomotor symptom
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scores improved. [In 2003, subsequent to this Swedish substudy, the larger, international,
multicenter HABITS trial (Hormonal replacement therapy after breast cancer – is it safe?)
was halted. Women allocated to receive MHT experienced a high rate of breast cancer
recurrence compared with women in non-hormonal treatment groups. All women on
MHT were recommended to stop treatment (Frisk et al., 2008; Frisk et al., 2012;
Holmberg & Anderson, 2004; Holmberg et al., 2008).]
A prospective, single-arm observational study was conducted to examine the
effect of traditional AP on vasomotor symptoms in women treated for early stage breast
cancer (n = 50, xˉ age = 54.3) and taking tamoxifen for at least 6 months (de Valois,
Young, Robinson, McCourt, & Maher, 2010). In addition to HF diaries, women
completed a measure of vasomotor symptom bother, and the Women‟s Health
Questionnaire (WHQ) which measures health-related quality of life. Traditional AP was
administered once weekly for eight weeks. Based on log transformed HF frequency data,
a mean HF reduction of 49.8% was seen at end of treatment (p < .0001). A significant
improvement was also seen in the vasomotor symptom bother score (p < .0001), which
was considered clinically significant. Paired samples t test results from the WHQ showed
a significant change in all domains except attractiveness, including improvement in the
memory/concentration domain (p = .0001). In addition, clinically meaningful
improvements were seen in 7 of the 9 WHQ domains, the exceptions being depressed
mood and attractiveness.
Kern and Cohen (2005) constructed a negative binomial, piecewise linear
regression model to determine treatment effectiveness of AP in a group of women treated
for breast cancer with menopausal symptoms. Women were assigned to one of three
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groups for a baseline monitoring week and 12 subsequent treatment weeks: an AP
treatment group, a non-symptom-specific placebo AP group, and an education group. The
AP groups received weekly treatments and the education group had weekly sessions on
healthy living. Only the AP treatment group (n = 16) and the education group (n = 6)
were considered in this analysis of self-reported daytime HF frequency data over 13
weeks; the placebo group was omitted as it did not further inform the model. When the
model was applied to the data, average daily HF frequency for the AP group dropped by
three over 13 weeks, with no noticeable increase or decrease seen in the education group.
Acupuncture studies for menopausal hot flashes vary in sample size and treatment
length, as well as in the types of acupuncture and acupuncture controls used. Most studies
having an acupuncture control arm found no significant difference in effect between
active and control acupuncture groups, with the exception of two studies that analyzed
results of the same trial (Huang et al., 2006; Nir et al., 2007) where a significant decrease
in HF frequency was seen in both AP groups, with significantly decreased HF severity in
the active AP group only. Given that the mechanism of acupuncture is not precisely
understood, this suggests that control procedures meant to be inert may have physiologic
effects (Lund & Lundeberg, 2006). In all studies examined here, acupuncture resulted in
decreased frequency of hot flashes, often reaching statistical significance. Menopausal
hormone therapy is more effective than AP in reducing vasomotor symptoms, but is not a
viable option for many women, especially those with breast cancer. These studies suggest
that acupuncture is a safe alternative that may help women with menopausal symptoms,
and that it merits further investigation.
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No AP studies were found that investigated menopause-related memory
difficulties as the primary outcome. Memory is frequently examined as a secondary
outcome using quality of life scales. Several studies measured memory as a specific
memory domain on the WHQ (Borud et al., 2009; de Valois et al., 2010; Frisk et al.,
2012), or part of a psychological domain on the MENQOL (Avis et al., 2008; Nir et al.,
2007; Painovich et al., 2012). In only one AP and HF study was a significant
improvement seen in a specific memory measure (WHQ) in response to AP treatment (de
Valois et al., 2010).

Conceptual Framework
The Framework for Interactions Between the Individual and the Environment
(Elliott & Eisdorfer, 1982) was developed in an effort to view stress research and other
work systematically and within a broader context of how the environment can affect the
individual. This model, used for the parent study, was chosen to guide this study. It is
consistent with the purpose of the study in providing a structure for examining the effect
of acupuncture on menopausal symptom of memory changes induced by natural
menopause or breast cancer treatment. It has been used as the framework for a study
exploring environmental uncertainty and nurse burnout (Garrett & McDaniel, 2001).
Activators are internal or external environmental conditions that change a
person‟s present state. Reactions are biological or psychosocial responses to an activator.
Consequences are sequelae of reactions, and may be biological, psychological, or
sociological, and desirable or undesirable. Activators, reactions and consequences can
occur at all levels of structural complexity, ranging from molecular to social. Mediators
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are modifiers that act on the sequence of activators, reactions and consequences. They
help to explain why some individuals experience a different number or severity of
consequences in response to the same activators or reactions (Elliott & Eisdorfer, 1982).
In this study, decreased ovarian activity during the menopausal transition or
secondary to cancer treatment becomes an Activator. The body responds to the Activator
which has the effect of decreasing serum estrogen levels leading to Reactions - the
menopausal symptoms of hot flashes and memory changes, among others. These
symptoms in turn may influence the ensuing Consequences of interference with daily
activities, symptom distress and decreased quality of life. Acupuncture is the Mediator
acting directly on the Reactions (a reduction in symptoms), and acting directly (solid line)
or indirectly (broken line) on Consequences (improvement in symptom distress) (see
Figure 2.1).
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Figure 2.1. Framework for Interactions Between the Individual and the Environment in
women treated for breast cancer receiving acupuncture for menopausal symptoms. Adapted from
Stress and human health: Analysis and implications of research (p. 19), by G.R. Elliott and C.
Eisdorfer (Eds.), 1982, New York: Springer Publishing Company. Adapted with permission.
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Chapter 3
Methods

Introduction
This chapter presents the methods used to answer the research questions of the
study. The parent study is presented first, followed by the current study. The discussion
addresses the design, subject recruitment, instruments, intervention, procedures for data
collection, protection of human subjects, and planned data analysis.

Study Design
Study aims were accomplished through secondary analysis of an existing data set
compiled for the randomized trial of Menopausal Symptom Relief for Women with
Breast Cancer (R01CA80625). Permission for the use of the database was obtained from
the principal investigator, Susan M. Cohen, DSN.

Overview of the Parent Study
Research design. The original study design was a placebo-controlled,
randomized clinical trial to explore the effect of acupuncture (AP) on menopausal
symptoms in breast cancer survivors. The study was single blind, with the researcher and
participants blinded on acupuncture group assignment (C. Vincent & Lewith, 1995). A
three-group design (site-specific AP, non-symptom specific AP, and enhanced usual care)
was used to explore the specific aims. Acupuncture treatment took the form of either
menopausal symptom-specific acupuncture (experimental group) or non-symptom
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specific needling at classical acupuncture point locations identified in the literature as not
relevant to the symptoms associated with menopause (AP control group). The enhanced
usual care group received education and materials on menopause symptom management
and healthy life activities provided by an educational interventionist.
Power analysis. A power analysis was performed for a three-group repeated
measures design. HF severity was used as the variable, and HF severity ratings from
Kronenberg (1990) were used in the calculation. A moderate effect size of .40 was used
based on findings of two studies on acupuncture treatment for menopausal symptoms
(Cohen et al., 2003; Wyon et al., 1995). For a power of .80 and α = 0.05, the number of
subjects needed in each group would be 9, or 27 total subjects. The sample size of the
parent study was expanded to 81 to compensate for a smaller effect size of other
menopausal symptoms, and to compensate for study attrition due to time commitment or
change in health status.
Variables.
Dependent variables. The dependent variables were:
1. Menopausal symptoms with hot flashes as the primary marker, mood changes, sleep
disturbances, and loss of concentration as measured by the Daily Symptom Diary and
modified Kupperman Index.
2. Quality of life as measured by the Menopause-Specific Quality of Life Questionnaire.
Independent variable. The independent variable was:
1. Acupuncture, site-specific for menopause.
Setting. The study was conducted through the Duquesne University and
University of Pittsburgh Schools of Nursing. Data were collected at an academic medical
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center in southwestern Pennsylvania. Interviews, educational sessions and acupuncture
treatments for all study participants took place at the medical center. This facility has four
acupuncture rooms available as well as private interview rooms.
Sample. A convenience sample was recruited from the general population of
women who experienced menopausal symptoms following diagnosis and completion of
treatment for breast cancer. A total of 254 women were screened, and 74 were
randomized to one of the three groups. Five women dropped out at randomization prior to
any intervention; 69 women were consented and completed baseline measurements.
Subjects were selected based on their self-identification of menopausal symptoms
that included hot flashes. Inclusion criteria included native English speaking, selfidentification of the menopausal symptom of hot flashes following treatment for breast
cancer (stage I or II) with subsequent verification of hot flashes on the one week baseline
Daily Symptom Diary, willingness to undergo acupuncture treatments for two months,
and willingness to record menopausal symptom frequency and severity on a daily basis.
Vitamins or other non-hormonal nutritional supplementation such as soy could be taken.
Exclusion criteria included concurrent treatment of menopausal symptoms with
hormonal supplementation, herbal remedies or acupuncture (including acupressure), nonhormonal pharmacologic agents prescribed for hot flash relief, or any drugs or conditions
known to affect cognitive function. Previous treatment of menopausal symptoms with
hormones, herbs or acupuncture must have ceased at least three months prior to
enrollment in the study to allow for a sufficient wash out period. Women with
lymphedema following surgery for breast cancer were excluded due to the possibility of
infection secondary to acupuncture treatments. Women who were presently in
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chemotherapy treatment for breast cancer were excluded due to the potential confounding
effect of needle acupuncture on chemotherapy side effects (NIH Consensus Development
Panel on Acupuncture, 1998). Women with diagnosed clinical depression were excluded
due to the effect of depression on cognitive function and quality of life.
Participants were recruited by flyers in oncology offices and clinics.
Advertisements were placed in local newspapers and on public transportation.
Subject enrollment. Recruitment materials included a phone number for
prospective participants to call for information. Initial screening of subjects took place
via telephone to verify inclusion/exclusion criteria. Subjects who met inclusion criteria
were given a full explanation of the study and invited to participate. A research assistant
met with the potential participant, explained the study, and gave the potential participant
an informed consent packet. After signing the informed consent form, study subjects
were oriented to the Daily Symptom Diary, and randomized into one of the three groups
using a table of random numbers.
Following enrollment, all subjects were interviewed in order to obtain
demographic information including information on breast cancer history and current
treatment. Quality of life measurement was obtained using the Menopause-Specific
Quality of Life Questionnaire. The Kupperman Index was used to screen for menopausal
symptoms, and the Center for Epidemiologic Studies Depression Scale was administered
to screen for depression at the enrollment session.
Measures.
Demographic data form. A demographic data form (Appendix A) was used to
gather basic information including menstrual history, breast cancer diagnosis, stage and
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treatments, as well as information on diet (including caffeine), exercise, medication
(including vitamins and nutritional supplements), and other self healing practices.
Center for Epidemiologic Studies Depression Scale. A screening test for
depression was administered using the Center for Epidemiologic Studies Depression
Scale (CES-D). Screening was done upon entry into the study. The CES-D is a 20 item
scale to determine clinical depression of recent origin (Radloff, 1977). It has high levels
of reliability and validity to detect both clinical and non-clinical symptoms of depression
(Andresen, Malmgren, Carter, & Patrick, 1994). Concurrent validity was established by
correlations with the Hamilton (r = 0.49 - 0.85) and Raskin (r = 0.28 - 0.79) Depression
Scales and the self report Symptom Checklist (r = 0.72 - 0.87) (Roberts & Vernon, 1983).
Women with clinical depression level scores (≥16) were excluded from the study and
were referred to their primary provider for assessment.
Daily Symptom Diary. A Daily Symptom Diary (Appendix B) was used to gather
data on the frequency of five menopausal symptoms (hot flashes, night sweats, mood
changes, sleep disturbances, and loss of concentration), as well as severity of hot flashes
and night sweats on a scale ranging from 0 (not present) to 3 (severe). The study design
included a one week baseline recording of menopausal symptoms, and eight weeks of
daily symptom recording during the treatment phase. Recording in the Daily Symptom
Diary is the usual format for collecting data in menstrual cycle research studies such as
menopausal symptom investigations (Sloan et al., 2001). Daily recordings are an
intensive method for collecting symptom data. However, women in previous studies
conducted by Cohen and associates (2003) have not perceived the daily recordings to be a
burden.
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Kupperman Index. A second measure for the menopausal symptom experience
was the modified Kupperman Index (Appendix C) which was administered by the
research assistant two additional times over the course of the study. It is a self-report
measure for that day of the severity of 10 menopausal symptoms, each rated on a scale of
0 (not present) to 3 (severe). Kupperman developed the Index to quantitatively record
symptoms associated with the menopausal transition. The Index assigns a higher number
to typical menopausal symptoms (e.g., hot flashes) by using a multiplication constant.
The items designated as symptoms are similar to those in the Daily Symptom Diary.
After multiplication by the constant, a summed total score indicated severity of
menopausal symptoms. A score of 15 or less indicated favorable therapeutic response
(Kupperman et al., 1953; Kupperman et al., 1959). The Index provides a check for any
missing data as well as a comparison for the Daily Symptom Diary recordings.
Reliability and validity evidence for the Daily Symptom Diary was addressed by
Bender and colleagues (2005). The relationship between the Daily Symptom Diary and
the Kupperman Index was analyzed. A nonparametric correlational analysis of hot flash
severity data from the Daily Symptom Diary and the Kupperman Index revealed a
correlation of 0.58 (p = .000), as well as a statistically significant correlation of 0.61 (p =
.000) between the Daily Symptom Diary and the Menopause-Specific Quality of Life
Questionnaire.
Menopause-Specific Quality of Life Questionnaire. Quality of life was measured
using the Menopause-Specific Quality of Life Questionnaire (MENQOL), a 29-item
questionnaire (Appendix D). The MENQOL has four domains of menopausal symptoms:
vasomotor, physical, psychosocial and sexual. Subjects indicated if they had experienced
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the symptoms and the extent of symptom bother in the past month. The MENQOL was
administered at baseline upon entry into the study, at the end of week five, and at the end
of the treatment phase (see Table 3.1). In their original work, Hilditch and associates
(1996) determined high face and content validity for the instrument. Test-retest reliability
(intraclass correlation coefficients) was vasomotor (0.37), physical (0.81), psychosocial
(0.79), and sexual (0.70). In a subsequent analysis, the vasomotor domain intraclass
correlation coefficient was 0.78 (Lewis, Hilditch, & Wong, 2005). Radtke and colleagues
(2011) examined the psychometric properties of the MENQOL in a sample of
postmenopausal breast cancer survivors, finding comparability to earlier psychometric
work done with this instrument, and concluding that the MENQOL appears to be a
reliable and valid tool for use in this population. A recent evaluation of the MENQOL
using factor analysis in a large sample (n = 2703) of healthy postmenopausal women
(Van Dole et al., 2012) determined reliability coefficients (Cronbach‟s α) for the four
original domains as follows: vasomotor (0.87), physical (0.88), psychosocial (0.85), and
sexual (0.77).

Table 3.1
Timeline of Measurements
End of 4th Treatment Week
(Week Five)

End of 8th Treatment Week
(Week Nine)

Daily Symptom Diary

Daily Symptom Diary

Daily Symptom Diary

Kupperman Index

Kupperman Index

Kupperman Index

MENQOL

MENQOL

MENQOL

Baseline
(Week One)
CES-D

Demographic Data Form
Note. CES-D = Center for Epidemiologic Studies Depression Scale; MENQOL = Menopause-Specific
Quality of Life Questionnaire
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Intervention.
Experimental group – Menopausal symptom-specific acupuncture. The
experimental acupuncture treatment consisted of specific acupuncture body points related
to menopausal symptoms, such as hot flashes, mood changes, sleep disturbances, and loss
of concentration. There were 12 acupuncture treatments over 8 weeks. The treatments
occurred twice per week for 4 weeks, and then once a week for 4 weeks. The treatments
lasted between 20 and 30 minutes. Acupuncture treatments were delivered by a single
acupuncturist licensed by the Commonwealth of Pennsylvania with extensive records
kept of each session. Needles were manually inserted and rotated to elicit the sensation of
de qi. The specific acupuncture points for the experimental group (site specific) were
taken from the traditional Chinese literature for women‟s complaints. Educational
materials were given to subjects following each acupuncture session (see Enhanced usual
care group).
Control group – Non-symptom-specific acupuncture. Non-symptom-specific
needling uses the technique of shallow acupuncture needle insertion at classical
acupuncture point locations thought to be irrelevant to the condition being treated. The
control acupuncture treatment consisted of needling at valid acupuncture points identified
in the literature as not associated with the symptoms of menopause. There were 12
acupuncture treatments over 8 weeks. The treatments occurred twice a week for 4 weeks
and then once a week for 4 weeks. The pattern was the same as in the experimental
group. The treatments lasted between 20 and 30 minutes. Acupuncture treatments were
delivered by a single acupuncturist licensed by the Commonwealth of Pennsylvania with
extensive records kept of each session. Needles were manually inserted. Educational
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materials were given to subjects following each acupuncture session (see Enhanced usual
care group).
Enhanced usual care group. The enhanced usual care group received educational
materials related to menopausal symptom management and healthy life activities at each
intervention point. There were 12 individual visits over 8 weeks. The 12 individual visits
occurred twice a week for 4 weeks and then once a week for 4 weeks. At each of the 12
individual visits, the participants received information on one of the following subjects:
healthy living, vitamins and minerals, exercise, relaxation, spirituality, herbal
supplements, sexuality, and self healing. Materials were prepared from published sources
concerning menopause symptom management. Records were kept of each session. The
educational sessions were standardized and taught by trained members of the research
team, all of whom had worked with menopausal women.
Data collection and management. The participants recorded their daily
menopausal symptoms using the Daily Symptom Diary for 9 weeks (one week at baseline
and every day during the eight treatment weeks). The symptom list of the diary contains
five possible menopausal symptoms as well as a space for subjects to include a selfidentified symptom. Subjects recorded the daily frequency and severity of the specific
symptom. The Symptom Diary is used to evaluate the changes in symptom pattern as a
result of the acupuncture treatment. Once a day at bedtime, subjects recorded the
frequency and severity of each menopausal symptom during the baseline and treatment
phases (total of 9 weeks) of the study. If a change in symptom frequency or severity was
attributed to a life event, each subject was asked to note the event in the area on the Daily
Symptom Diary called “Events affecting Symptoms.”
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At entry into the study, and every four weeks during the treatment phase, subjects
were interviewed about the severity of their symptoms using the modified Kupperman
Index. The MENQOL was administered upon entry into the study to establish baseline
values, at the end of four weeks of treatment, and at the end of the last treatment. All
three groups received the same number of subject contacts. The contacts included an
initial interview, and twelve intervention sessions.
Each of the participants in the study contributed a significant amount of data. The
data instruments gathered information on menopausal symptom experience and quality of
life. Upon entry into the study, each participant received a unique study number. With the
exception of the consent form and address/phone information, all study instruments carry
only the assigned study number.
Once data forms were completed, data were entered into a computerized data base
for statistical analysis. The original data forms are kept in a locked file in the principal
investigator‟s research office. The electronic data are kept in a password protected
section of the Center for Research and Evaluation server in the University of Pittsburgh
School of Nursing. Only the principal investigator, the statistician and the data manager
have access to the electronic data set.

Current Study
Protection of Human Subjects. Prior to data analysis, approval was obtained
from the Duquesne University Institutional Review Board. No new or additional data
were collected, and no additional subjects were enrolled for this secondary analysis. The
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data were de-identified by a certified person at the University of Pittsburgh School of
Nursing. Data were obtained in person from the principal investigator.
Data analysis. IBM® SPSS® Statistics 20 Premium GradPack and SAS® 8.2
were used to analyze the data. Frequency distributions and descriptive statistics were
used to summarize the data. Frequency distributions are presented in both tabular and
graphic form. Categorical variables were compared using the Cochran-Mantel-Haenszel,
Fisher‟s exact, and chi-square tests as appropriate. Continuous data were compared using
analysis of variance (ANOVA), repeated measures ANOVA, or equivalent nonparametric tests as appropriate. A two-tailed significance level of .05 was used. Missing
data were assessed for extent and pattern of missingness. Missing data were deemed to be
missing completely at random. Overall, approximately 3.7% of all observations were
missing, which is considered to be negligible in a study of this type (F. Mandel, personal
communication, February 28, 2013). After discussion with the consulting statistician and
dissertation committee chair, it was determined that no imputation should be done.
Research questions.
Question 1. What are the effects of menopausal symptom-specific acupuncture on
memory in breast cancer survivors with menopausal symptoms?
Hypothesis 1a. Menopausal symptom-specific acupuncture will improve
perceived memory changes as measured by self-reports compared to enhanced usual care
(education).
Hypothesis 1b. Non-symptom-specific acupuncture will improve
perceived memory changes as measured by self-reports compared to the enhanced usual
care (education) group.
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Question 2. Is there a relationship between improvements in hot flashes/night
sweats and perceived memory changes in breast cancer survivors with menopausal
symptoms?
Each subject contributed seven days of daily frequency counts of HF, NS and loss
of concentration at three time points: at week 1 (baseline), week 5, and week 9. Symptom
ratings from the two other instruments were examined at the same time points. The
Kupperman Index measured subjects‟ self-reports of symptom severity for that particular
day on a scale of 0-3. On the MENQOL, symptom severity experienced over the past
month, if present, was rated on a scale of 0-6.
To analyze the effect of acupuncture on memory, a repeated measures ANOVA
was used to compare the three treatment groups on the data from the Daily Symptom
Diary. Change from baseline was examined on the Daily Symptom Diary, Kupperman
Index, and MENQOL using frequency distributions to compare changes in memory
reports at baseline to week 5, baseline to week 9, and week 5 to week 9. Pairwise
comparisons were performed as necessary.
Although planned, regression analysis to examine if improvement in HF/NS was a
predictor of improvement in memory was not pursued. Due to non-significant findings on
data from the Daily Symptom Diary, and considerable stability in the proportions of
change seen in data from the Kupperman Index and MENQOL, further analyses were not
conducted.
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Chapter 4
Data Analysis

Introduction
This chapter describes the results of the data analysis. A description of the sample
is presented, followed by the results as they relate to the research questions of the study.

Description of the Sample
In the parent study, a convenience sample of women who were experiencing
menopausal symptoms following diagnosis and treatment for breast cancer was recruited.
Subjects were selected based on their self-identification of menopausal symptoms, and
completion of cancer treatment. Two hundred fifty-four women were screened, and 74
were randomized to one of three groups: non-symptom- specific acupuncture (AP
control), menopausal symptom-specific acupuncture (AP specific), and enhanced usual
care (EUC). Five women dropped out at randomization; 69 women were consented and
completed baseline measurements.
The sample of women for this study (n = 60) was derived from the parent study.
All subjects in the parent study who indicated loss of concentration and/or experiencing
poor memory at baseline on any one of the three instruments measuring menopausal
symptoms were included in this study. Participant characteristics from the Demographic
Data Form are described in Table 4.1. One-way analysis of variance (ANOVA) and chisquare tests were conducted to examine between-group differences. The three groups
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were not significantly different in age, age at menopause, or in chemotherapy and
adjuvant hormone therapies received as treatment for breast cancer.

Table 4.1
Sample Characteristics
Age (years)
Total
n = 60

AP control
n = 20

AP specific
n = 22

EUC
n = 18

F

p

Age at study entry
xˉ (SD)
range (min, max)

53 (5.6)
31 (37, 68)

54.4 (5.3)
22 (46, 68)

52.6 (5.2)
17 (47, 64)

51.8 (6.3)
26 (37, 63)

1.12

.33

Age at menopausea
xˉ (SD)
range (min, max)

47.2 (4.5)
22 (34, 56)

48.7 (4.8)
22 (34, 56)

46.3 (4.2)
19 (34, 53)

46.8 (4.5)
17 (37, 54)

1.55

.22

Total
n (%)

AP control
n (%)

AP specific
n (%)

EUC
n (%)

χ2

p

Previous chemotherapy

33 (61.1)

9 (50)

15 (78.9)

9 (52.9)

3.96

.14

Current tamoxifen

25 (43.9)

7 (38.9)

9 (42.9)

9 (50)

0.47

.79

Current aromatase
inhibitor

5 (9.1)

2 (11.1)

2 (9.5)

1 (6.3)

0.25

.88

Treatment

Note. AP, acupuncture; EUC, enhanced usual care.
a
n = 56: four missing values (two AP control, one AP specific, one enhanced usual care).

Research Questions
Research Question 1. What are the effects of menopausal symptom-specific
acupuncture on memory in breast cancer survivors?
Instruments. Three instruments were used to gather data on the menopausal
symptom of memory changes. The Daily Symptom Diary will be addressed first,
followed by the Kupperman Index and the Menopause-Specific Quality of Life
Questionnaire (MENQOL).
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Daily Symptom Diary. The data examined in this study generated by the Daily
Symptom Diary are frequencies of menopausal symptoms. Memory changes are termed
„loss of concentration‟ in this instrument. At the time points of week one (baseline), week
five and week nine, memory data included in this analysis were the total number of
episodes of loss of concentration reported by the subjects over the 7 days of that
particular week. Though loss of concentration is the main variable of interest, hot flash
and night sweat data from the Daily Symptom Diary are also presented as they are
important aspects of the menopausal symptom experience, and may further inform the
loss of concentration data. Table 4.2 presents the symptom frequencies of the total
sample from the Daily Symptom Diary at baseline.

Table 4.2
Overall Symptom Frequency from Daily Symptom Diary at Baseline Regardless of
Group
Hot Flashes
n = 60

Night Sweats
n = 60

Loss of Concentration
n = 60

xˉ (SD)

47.4 (25.8)

16.3 (14.2)

9 (14.0)

median (Q1, Q3)

40 (25, 65.5)

13 (8.5, 21.5)

5 (0, 9.5)

range (min, max)

116 (6, 122)

88 (0, 88)

72 (0, 72)

th

th

Note. Q1 = 25 percentile, Q3 = 75 percentile [interquartile range]. Symptom frequency is per week in all
symptom categories.

One-way ANOVA testing on these baseline symptom frequencies suggests there are no
significant differences between the two AP groups and the enhanced usual care group, as
seen in Table 4.3.
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Table 4.3
Group Differences in Symptom Frequency from Daily Symptom Diary at Baseline
AP control
n = 20

AP specific
n = 22

EUC
n = 18

Hot flashes
xˉ (SD)
range (min, max)

53.0 (23.1)
73 (25, 98)

40.1 (23.1)
83 (14, 97)

Night sweats
xˉ (SD)
range (min, max)

19.5 (17.7)
88 (0, 88)

11.6 (8.5)
31 (0, 31)

F

p

50.2 (30.7)
116 (6, 122)

1.46

.24

18.4 (14.8)
56 (0, 56)

1.95

.15

Loss of concentration
xˉ (SD)
14.0 (21.4)
8.4 (8.7)
4.3 (4.7)
2.4
range (min, max)
72 (0, 72)
31 (0, 31)
13 (0, 13)
Note. AP, acupuncture; EUC, enhanced usual care. Symptom frequency is per week in all symptom
categories.

.10

Kupperman Index. This instrument is a self-report of the perceived severity of 10
menopausal symptoms, including loss of concentration and hot flashes. The severity
rating for each symptom ranges from 0 to 3: not present = 0, mild = 1, moderate = 2, and
severe = 3. The Kupperman Index was administered once at each of the three time points.
The total sample baseline severity ratings for loss of concentration and hot flashes are
described in Table 4.4.

Table 4.4
Overall Symptom Severity Rating from Kupperman Index at Baseline Regardless of
Group
Hot Flashes
n = 60

Loss of Concentration
n = 60

xˉ (SD)

2.5 (0.62)

1.48 (0.79)

median (Q1, Q3)

3 (2,3)

1 (1,2)

range (min, max)

2 (1,3)

3 (0,3)

Note. Severity rating: 0 = not present; 1 = mild; 2 = moderate; 3 = severe. Q1 = 25 th percentile, Q3 = 75th
percentile [interquartile range].
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Analysis of differences between groups at baseline with one-way ANOVA tests did not
reach significance on loss of concentration ratings, F(2,57) = 1.21, p = .31, or on ratings
of hot flashes, F(2,57) = 0.85, p = .43 (see Table 4.5).

Table 4.5
Group Differences in Symptom Severity Rating from Kupperman Index at Baseline
AP control
n = 20

AP specific
n = 22

EUC
n = 18

Hot flashes
xˉ (SD)
range (min, max)

2.6 (0.6)
2 (1, 3)

2.4 (0.7)
2 (1, 3)

Loss of concentration
xˉ (SD)
range (min, max)

1.4 (0.8)
3 (0, 3)

1.4 (0.9)
3 (0, 3)

F

p

2.6 (0.6)
2 (1, 3)

0.85

.43

1.7 (0.8)
3 (0, 3)

1.21

.31

Note. AP, acupuncture; EUC, enhanced usual care.

Menopause-Specific Quality of Life Questionnaire. The MENQOL was
administered once at each of the three time points. It is a self-report instrument where
subjects rate the perceived severity of a symptom, only if they are experiencing that
symptom. The 0 to 6 severity rating for each symptom ranges from “not at all bothered”
to “extremely bothered.” For this study, bother is interpreted as an indication of symptom
severity. The memory item in this instrument is „experiencing poor memory,‟ with hot
flashes and night sweats also rated. The baseline severity ratings for these three variables
by the total sample are shown in Table 4.6.
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Table 4.6
Overall Symptom Severity Rating from MENQOL at Baseline Regardless of Group
Hot Flashes
n = 60

Night Sweats
n = 54a

Experiencing Poor Memory
n = 55b

xˉ (SD)

4.72 (1.33)

4.13 (1.67)

3.11 (1.49)

median (Q1, Q3)

5 (4, 6)

4 (3,6)

3 (2,4)

range (min, max)

5 (1,6)

5 (1, 6)

6 (0, 6)

Note. MENQOL, Menopause-Specific Quality of Life Questionnaire. Severity rating scale from 0 to 6 (not
at all bothered to extremely bothered). Q1 = 25th percentile, Q3 = 75th percentile [interquartile range].
a
Six subjects reported having no night sweats. bFive subjects reported not experiencing poor memory.

Analysis of differences between groups at baseline with one-way ANOVA tests did not
reach significance on poor memory ratings, F(2,52) = 0.18, p = .84; hot flash ratings,
F(2,57) = 0.93, p = .40; or night sweat ratings, F(2,51) = 1.11, p = .34 (see Table 4.7).

Table 4.7
Group Differences in Symptom Severity Rating from MENQOL at Baseline

Hot flashes
xˉ (SD)
range (min, max)

Night sweats
xˉ (SD)
range (min, max)

Experiencing poor memory
xˉ (SD)
range (min, max)

AP control
n = 20

AP specific
n = 22

EUC
n = 18

4.9 (1.3)
4 (2, 6)

4.4 (1.4)
5 (1, 6)

4.9 (1.3)
5 (1, 6)

n = 18

n = 21

n = 15

4.0 (1.8)
5 (1, 6)

3.9 (1.7)
5 (1, 6)

4.7 (1.5)
5 (1, 6)

n = 18

n = 22

n = 15

2.9 (1.6)
6 (0, 6)

3.2 (1.7)
6 (0, 6)

3.1 (1.0)
3 (2, 5)

F

p

0.93

.40

1.11

.34

0.18

.84

Note. AP, acupuncture; EUC, enhanced usual care

Hypothesis testing. There are two hypotheses that address the first research
question. Hypothesis 1a. Menopausal symptom-specific acupuncture will improve
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perceived memory changes as measured by self-reports compared to enhanced usual care
(education). Hypothesis 1b. Non-symptom-specific acupuncture will improve perceived
memory changes as measured by self-reports compared to enhanced usual care
(education). These hypotheses will be addressed in this section.
Daily Symptom Diary. The data considered to best answer this research question
were frequency data from the Daily Symptom Diary, as more data were collected from
each subject using this method. The proposed statistical test for this question was
repeated measures ANOVA. The assumptions of parametric tests are: normally
distributed data, homogeneity of variance, data measured at least at the interval level, and
independence. In repeated measures, the assumption of independence is automatically
violated, and the additional assumption of sphericity is included (Field, 2009).
For memory data from the Daily Symptom Diary, normality of the data was
examined by construction of histograms and P-P plots, evaluation of skewness and
kurtosis, and Kolmogorov-Smirnov tests. These showed that the distribution of the data
was not normal. Levene‟s test for homogeneity of variance showed that the variances
were significantly different at baseline week, F(2,53) = 7.19, p = .002, indicating a
violation of the assumption. As the data are not normally distributed and variances are
significantly different, the conclusions of the repeated measures ANOVA may not be
replicable.
Repeated measures ANOVA results for loss of concentration frequencies from the
Daily Symptom Diary are as follows. Mauchly‟s test indicated that the assumption of
sphericity had been violated, χ2(2) = 57.81, p < .001, therefore degrees of freedom were
corrected using the Greenhouse-Geisser estimates of sphericity (ε = .59). No significant
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main effects or interactions were found. The group x time interaction (F(2.39, 63.44) =
1.92, p = .15), the main effect for time (F(1.20, 63.44) = 2.77, p = .10), and the main
effect for group (F(2, 53) = 1.73, p = .19) were not significant. Frequency of loss of
concentration was not influenced by either time or treatment group.
As the assumptions for repeated measures ANOVA were not met, additional
analyses based on frequency distributions were used to further investigate the data. The
loss of concentration data from the Daily Symptom Diary were analyzed to examine
change in symptoms of all subjects regardless of group from baseline to week 5, baseline
to week 9, and week 5 to week 9. Frequencies of loss of concentration episodes at week 5
and at week 9 were subtracted from those at baseline, and frequencies at week 9 were
subtracted from those at week 5. The data were categorized as follows: negative numbers
indicated an increase in symptom frequency (worsening), a zero indicated no change, and
positive numbers indicated a decrease in symptom frequency (improvement). The range
of frequency counts from baseline to week 5 was -21 to +72, range from baseline to week
9 was -14 to +72, and -11 to + 18 from week 5 to week 9. In order to analyze this data,
changes in frequency ratings were categorized as worse (-21 to -1), stayed the same
(zero), or improved (+1 to +72) during the time period examined. Results are shown in
Table 4.8.
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Table 4.8
Overall Change in Loss of Concentration Frequency Ratings Regardless of Group (Daily
Symptom Diary)
Worse
n (%)

Samea
n (%)

Improved
n (%)

Baseline to Week 5 (n = 58)

20 (34.5)

15 (25.9)

23 (39.6)

Baseline to Week 9 (n = 56)

16 (28.6)

13 (23.2)

27 (48.2)

Week 5 to Week 9 (n = 56)

16 (28.6)

18 (32.1)

22 (39.3)

Note. aSame = no change (difference equal to zero).

To further examine frequency of change in loss of concentration and treatment
group, frequency counts from baseline to week 5, baseline to week 9, and week 5 to week
9 were collapsed. The categories were as follows: lowest negative number to -5 = worse,
scores of -4 to +4 = stayed the same, and +5 to the highest number = improved. To
eliminate small changes that were unimportant, „stayed the same‟ was defined using the
range -4 to +4, which is approximately one-half an episode of loss of concentration per
day. Using these categories, 3x3 tables were constructed using treatment group and
frequency ratings. Group changes in symptom frequency were compared from baseline to
week 5, baseline to week 9, and week 5 to week 9. Because of low expected frequencies
in some cells, the assumptions of the chi-square test were not met, and Fisher‟s exact test
was used (Field, 2009). No significant difference was seen between groups in the change
of symptom frequency of loss of concentration from baseline to week 5, from baseline to
week 9, or from week 5 to week 9 (see Table 4.9).
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Table 4.9
Change in Loss of Concentration Frequency Ratings Between Groups (Daily Symptom
Diary): Baseline to Week 5, Baseline to Week 9, Week 5 to Week 9
Worse
n (%)

Samea
n (%)

Improved
n (%)

p

AP control (n = 19)

2 (10.5)

12 (63.2)

5 (26.3)

.09

AP specific (n = 21)

3 (14.2)

9 (42.9)

9 (42.9)

Enhanced usual care (n = 18)

3 (16.7)

14 (77.8)

1 (5.5)

Worse
n (%)

Samea
n (%)

Improved
n (%)

p

AP control (n = 19)

2 (10.5)

11 (57.9)

6 (31.6)

.19

AP specific (n = 20)

2 (10.0)

9 (45.0)

9 (45.0)

Enhanced usual care (n = 17)

5 (29.4)

10 (58.8)

2 (11.8)

Worse
n (%)

Samea
n (%)

Improve
n (%)

p

AP control (n = 19)

1 (5.3)

15 (78.9)

3 (15.8)

.15

AP specific (n = 20)

0 (0)

16 (80.0)

4 (20.0)

Enhanced usual care (n = 17)

4 (23.5)

12 (70.6)

1 (5.9)

Baseline to Week 5

Baseline to Week 9

Week 5 to Week 9

a

Note. AP, acupuncture. Same = difference between -4 and +4.

Kupperman Index. An analysis of severity of loss of concentration from the
Kupperman Index was added to further explore this symptom in this population. This
instrument was administered once at baseline, at week 5, and at week 9. Subjects were
asked to rate the severity of the symptom of loss of concentration for that day. Symptom
severity ratings were 0 = not present, 1 = mild, 2 = moderate, and 3 = severe. Using the
actual rating scores, 3-group by 4 x 4 frequency tables were constructed in order to
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compare group change in symptom scores from baseline to week 5, baseline to week 9,
and week 5 to week 9. Changes in severity ratings were categorized as worse, stayed the
same, or improved during the time period examined. Analysis of frequencies was chosen
over the Friedman test as the latter examines data only at a particular observation point
and does not show change. The Cochran-Mantel-Haenszel statistic was used to test
whether proportions of change were the same in all groups. Change in severity ratings on
the Kupperman Index for loss of concentration was significantly different between
groups from baseline to week 5, χ2(1) = 8.37, p = .004, from baseline to week 9, χ2(1) =
4.71, p = .03, and from week 5 to week 9, χ2(1) = 16.52, p < .0001.
Post hoc testing was conducted to examine pairwise differences among the three
groups. Because of multiple comparisons within the same analysis, a Bonferroni
correction was used to determine significance at p < .0167. As shown in Table 4.10,
comparisons of change in severity ratings from baseline to week 5 were significantly
different between the AP control and enhanced usual care groups, χ 2(1) = 7.72, p = .006,
and between the AP specific and enhanced usual care groups, χ2(1) = 7.21, p = .007. No
significant difference was seen in comparison of the AP specific and AP control groups.
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Table 4.10
Pairwise Comparisons – Change in Loss of Concentration Severity Ratings (Kupperman):
Baseline to Week 5
Baseline to Week 5

Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 20)

3 (15)

9 (45)

8 (40)

11 (55)

7.72

.006

EUC (n = 18)

0 (0)

9 (50)

9 (50)

9 (50)

AP specific (n = 21)

5 (24)

5 (24)

11 (52)

16 (76)

7.21

.007

EUC (n = 18)

0 (0)

9 (50)

9 (50)

9 (50)

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.

For the period of baseline to week 9, the AP control and enhanced usual care
groups were significantly different, χ2(1) = 6.54, p = .011 (see Table 4.11). The
comparisons of change in the AP specific and enhanced usual care groups, and AP
specific and AP control groups did not reach significance.

Table 4.11
Pairwise Comparisons – Change in Loss of Concentration Severity Ratings (Kupperman):
Baseline to Week 9
Baseline to Week 9

Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 18)

4 (22)

7 (39)

7 (39)

11 (61)

6.54

.011

EUC (n = 18)

0 (0)

6 (33)

12 (67)

12 (67)

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.

For the period of week 5 to week 9 shown in Table 4.12, the change in severity of
loss of concentration ratings was significantly different for the AP control and enhanced
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usual care groups, χ2(1) = 18.36, p < .0001, and for the AP specific and AP control
groups, χ2(1) = 11.04, p = .0009. No significant difference was seen in comparing the AP
specific and enhanced usual care groups.

Table 4.12
Pairwise Comparisons – Change in Loss of Concentration Severity Ratings (Kupperman):
Week 5 to Week 9
Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 18)

2 (11)

14 (78)

2 (11)

4 (22)

18.36

< .0001

EUC (n = 18)

3 (17)

8 (44)

7 (39)

10 (56)

AP control (n = 18)

2 (11)

14 (78)

2 (11)

4 (22)

11.04

.0009

AP specific (n = 21)

4 (19)

12 (57)

5 (24)

9 (43)

Week 5 to Week 9

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.

As seen above, the two AP groups from week 5 to week 9 differed significantly
from each other, but not at any other time point. The AP specific group showed more
change than did the AP control group. Fewer severity scores stayed the same, and change
was seen in both the improved and worse directions.
From baseline to week 5, both AP groups showed significant change from the
enhanced usual care group, with severity ratings having a greater trend toward worsening
than those of the enhanced usual care group. From baseline to week 9, and from week 5
to week 9, there was more change toward improvement in the enhanced usual care group
than in the AP control group, indicating that improvement in the enhanced usual care
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group ratings occurred after the midpoint of the treatment phase. These results are
illustrated in Figure 4.1.

Figure 4.1. Comparisons of change in severity ratings of loss of concentration between
groups using pairwise comparisons (Kupperman Index). AP, acupuncture; EUC, enhanced usual
care; APC, acupuncture control; APS, acupuncture specific.
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Menopause-Specific Quality of Life Questionnaire. An analysis of experience of
poor memory from the MENQOL was undertaken to further explore this symptom. This
instrument was administered once at baseline, at week 5, and at week 9. Subjects were
asked whether or not they experienced poor memory in the past month. If yes, subjects
then rated the symptom on a scale of 0 to 6 from “not at all bothered” to “extremely
bothered” (interpreted in this study as perceived severity of the symptom).
Frequencies of actual severity scores were examined by treatment group at
baseline, week 5, and week 9. A category was included to capture women who indicated
they did not experience poor memory at a particular time point, and thus did not rate
severity at that time, but may have rated severity at another of the time points. Fisher‟s
exact test was used. There were no differences seen between groups in actual severity
scores at baseline (p = .54), at week 5 (p = .72), or at week 9 (p = .35).
The change in severity for experiencing poor memory was analyzed using
frequency tables to compare the AP control, AP specific and enhanced usual care groups
from baseline to week 5, baseline to week 9, and week 5 to week 9. Changes in severity
ratings were categorized as worse, stayed the same, or improved during the time period
examined. The Cochran-Mantel-Haenszel statistic was used to determine if proportions
of change were the same in all groups. Change in severity ratings on the MENQOL for
experiencing poor memory was significantly different between groups from baseline to
week 5, χ2(1) = 11.3, p = .0008; from baseline to week 9, χ2(1) = 17.9, p < .0001; and
from week 5 to week 9, χ2(1) = 28.7, p < .0001.
Post hoc testing was done to evaluate pairwise differences among the three
groups, with a Bonferroni correction used to determine significance at p < .0167.
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Comparisons of change in severity ratings from baseline to week 5 (see Table 4.13),
baseline to week 9 (see Table 4.14), and week 5 to week 9 (see Table 4.15) showed a
significant difference for the AP specific and AP control groups, AP specific and
enhanced usual care groups, and AP control and enhanced usual care groups at every
time point. All three groups were significantly different from each other in the proportion
of subjects that remained the same, worsened, and showed improvement.

Table 4.13
Pairwise Comparisons – Change in Severity Ratings for Experiencing Poor Memory
(MENQOL): Baseline to Week 5
Baseline to Week 5

Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 18)

9 (50)

1 (6)

8 (44)

17 (94)

6.49

.011

EUC (n = 18)

5 (28)

4 (22)

9 (50)

14 (78)

AP specific (n = 17)

4 (23)

3 (18)

10 (59)

14 (82)

8.25

.004

EUC (n = 18)

5 (28)

4 (22)

9 (50)

14 (78)

AP control (n = 18)

9 (50)

1 (6)

8 (44)

17 (94)

8.05

.005

AP specific (n = 17)

4 (23)

3 (18)

10 (59)

14 (82)

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.
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Table 4.14
Pairwise Comparisons – Change in Severity Ratings for Experiencing Poor Memory
(MENQOL): Baseline to Week 9
Baseline to Week 9

Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 18)

4 (22)

1 (6)

13 (72)

17 (94)

11.38

.0007

EUC (n = 18)

6 (33)

3 (17)

9 (50)

15 (83)

AP specific (n = 21)

2 (10)

3 (14)

16 (76)

18 (86)

13.04

.0003

EUC (n = 18)

6 (33)

3 (17)

9 (50)

15 (83)

AP control (n = 18)

4 (22)

1 (6)

13 (72)

17 (94)

11.40

.0007

AP specific (n = 21)

2 (10)

3 (14)

16 (76)

18 (86)

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.

Table 4.15
Pairwise Comparisons – Change in Severity Ratings for Experiencing Poor Memory
(MENQOL): Week 5 to Week 9
Worse
n (%)

Same
n (%)

Improved
n (%)

Total change
n (%)

χ2

p

AP control (n = 16)

4 (25)

7 (44)

5 (31)

9 (56)

19.01

< .0001

EUC (n = 18)

6 (33)

9 (50)

3 (17)

9 (50)

AP specific (n = 17)

1 (6)

5 (29)

11 (65)

12 (71)

20.08

< .0001

EUC (n = 18)

6 (33)

9 (50)

3 (17)

9 (50)

AP control (n = 16)

4 (25)

7 (44)

5 (31)

9 (56)

18.87

< .0001

AP specific (n = 17)

1 (6)

5 (29)

11 (65)

12 (71)

Week 5 to Week 9

Note. AP, acupuncture; EUC, enhanced usual care. Total change is subjects who either worsened or
improved.
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From baseline to week 5 and baseline to week 9, the severity ratings in the AP
control group appeared to worsen more than did ratings in the AP specific group, with the
AP specific group scores showing improvement from week 5 to 9. This suggests a
positive trend for scores in the AP specific group compared to those in the AP control
group, with more improvement seen in the AP specific group in the latter half of the
treatment phase. In comparison to ratings of the enhanced usual care group, the AP
control group scores showed more change at all time points, with initial worsening seen
from baseline to week 5, and improvement from baseline to week 9, and weeks 5 to 9. At
all time points, the scores of the AP specific group showed greater change and a trend
toward improvement compared with scores in the enhanced usual care group. Symptom
severity scores in both AP groups appeared to show greater improvement over time than
those in the enhanced usual care group (see Figure 4.2).
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Figure 4.2. Comparisons of change in severity ratings for experiencing poor memory
between groups using pairwise comparisons (MENQOL). AP, acupuncture; EUC, enhanced usual
care; APC, acupuncture control; APS, acupuncture specific; MENQOL, Menopause-Specific
Quality of Life Questionnaire.
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Hypothesis 1a. The null hypothesis assumes that menopausal-symptom specific
acupuncture will not improve perceived memory changes as measured by self-reports
compared to enhanced usual care. No significant difference was seen over time on
frequency of loss of concentration episodes from the Daily Symptom Diary. The null
hypothesis was not rejected.
Hypothesis 1b. The null hypothesis assumes that non-symptom-specific
acupuncture will not improve perceived memory changes as measured by self-reports
compared to enhanced usual care. No significant difference was seen over time on
frequency of loss of concentration episodes from the Daily Symptom Diary. The null
hypothesis was not rejected.

Research Question 2. Is there a relationship between improvements in hot
flashes/night sweats and perceived memory changes in breast cancer survivors with
menopausal symptoms? No significant differences were seen over time between
treatment groups on frequency of loss of concentration episodes from the Daily Symptom
Diary. Further examination of the diary data using frequency distributions showed no
significant differences when comparing group change in loss of concentration from
baseline to week 5, week 5 to week 9, and baseline to week 9.
Results from the MENQOL showed significant differences in the proportion of
change in experiencing poor memory between all groups at all time points. The proposed
analysis utilizing correlation and multiple regression was considered to examine the
relationship of improvement in hot flashes/night sweats and memory using the MENQOL
data. However, a large proportion of subjects “stayed the same” from baseline to week 5,
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week 5 to week 9, and baseline to week 9, and would therefore be eliminated from the
analysis. An insufficient number of subjects would remain to obtain an informative result.
Based on these characteristics of the data, no further analysis was attempted.

Summary
This study examined the effectiveness of acupuncture on menopause-related
memory complaints of women with breast cancer. The women in the AP control, AP
specific, and enhanced usual care groups were not significantly different in age, age at
menopause, or breast cancer treatments of chemotherapy and adjuvant hormone
therapies. Mean frequency or severity of menopausal symptoms was not different
between groups at baseline on any of the three instruments used.
Data on frequency of loss of concentration from the Daily Symptom Diary were
identified as the best data available to explore the research questions. Repeated measures
ANOVA on daily diary data showed that frequency of loss of concentration was not
influenced by either time or treatment group. Further analysis using frequency tables to
determine change in symptom frequency between groups did not reach significance at
any time point.
The Kupperman Index was administered three times, and measured subjects‟ selfreports of symptom severity for that particular day. Frequencies using data from the
Kupperman Index were analyzed to examine the proportion of change between groups in
severity ratings of loss of concentration, which reached significance at all time points.
Post hoc testing showed significant differences between some groups with an overall
trend toward improvement in the enhanced usual care group compared to the AP groups.
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Subjects completed the MENQOL three times, and reported severity of their
symptoms, if present, on a scale of 0-6. Examination of frequencies to determine the
proportion of change between groups in severity ratings of experiencing poor memory
reached significance. In post hoc testing, all three groups were significantly different
from each other at every time point. Overall, the AP specific group showed more
improvement than the AP control and enhanced usual care groups, with the AP control
group showing more improvement than the enhanced usual care group in the second half
of the treatment phase.
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Chapter 5
Discussion

Introduction
The impetus for this secondary data analysis was the prevalence of memory
complaints by postmenopausal women and by breast cancer survivors, and the lack of
research on the menopausal symptom of memory changes in response to acupuncture
treatment. The need for non-pharmacologic interventions for relief of menopausal
symptoms, particularly in women with breast cancer, has been well documented (Knobf,
2011; Woods & Mitchell, 2011).
The Framework for Interactions Between the Individual and the Environment,
introduced in Chapter 2, guided the study (Elliott & Eisdorfer, 1982). The internal
environmental change of natural or treatment-induced menopause, and subsequent
decline in estrogen (Activator), may lead to the experience of a number of symptoms
attributed to menopause (Reactions). Consequences such as symptom bother and
decreased quality of life are the individual‟s response to prolonged or cumulative effects
of reactions. The elements of the model are not static, and continually interact with and
are modified by each other. Reactions to an activator may be transient and produce no
remarkable consequences, or may be sufficiently intense as to result in considerable
consequences. For example, vasomotor symptoms reported by breast cancer survivors are
more severe than those described by healthy women (Carpenter et al., 2002; Mar Fan et
al., 2010). Acupuncture, the Mediator in the model for this study, was examined for its
effect on the Reactions, specifically on the symptom of perceived memory changes.
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An aspect of the model pertinent to this particular analysis is that activators can
be potential activators under some circumstances. This acknowledges that the internal
environment, or activator, of reduced estrogen may not be the actual or sole activator, or
the activator in all women. As new data emerges, the model keeps the door open for
potential activators such as genetic susceptibility, stress of a cancer diagnosis, cancer
treatment, or the biology of the disease itself (Ahles, Root, & Ryan, 2012; Cimprich et
al., 2010). Inherent in the model is that reactions to an activator may vary in intensity
from one individual to another and within the same individual at different times, which
was seen in the measurements of symptom frequency and severity in this study at three
time points. This model acknowledges that reactions that produce consequences may not
be completely understood, thus tolerating the current lack of understanding of the
etiology of cognitive changes in menopausal women and breast cancer survivors (Ahles
& Saykin, 2007). Mediators may be biological and psychological, supporting the
inclusion of acupuncture in the model despite its unknown mechanism of action.
Mediators can vary in their effect on individuals, which was observed in the outcomes of
this study.
The primary purpose of this study was to examine the efficacy of acupuncture to
improve the menopausal symptom of memory changes in breast cancer survivors. A
discussion of the findings is presented here in relation to the research questions and
pertinent literature. Limitations of the study, suggestions for future research and
implications for nursing practice are included.
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Discussion of Results
Demographic Findings. A convenience sample of breast cancer survivors who
were experiencing menopausal symptoms was recruited for the parent study. Subjects
were selected based on their self-identification of menopausal symptoms, and completion
of cancer treatment. These women were randomized to one of three groups: nonsymptom-specific acupuncture (AP control), menopausal symptom-specific acupuncture
(AP specific), and enhanced usual care.
The sample of women in this secondary analysis are those in the parent study who
indicated loss of concentration or experiencing poor memory at baseline on any one of
the three instruments measuring menopausal symptoms. The frequency and severity of
memory symptoms indicated on the three instruments did not differ between groups at
baseline. As might be anticipated in a randomized trial, there were no differences
between groups at baseline in age, age at menopause, previously having received
chemotherapy, or currently taking adjuvant hormonal therapy. The age range of 37 to 68
years in this sample is similar to that in other studies examining the effect of acupuncture
on the menopausal symptom experience of breast cancer survivors (de Valois et al., 2010;
Frisk et al., 2008; Nedstrand et al., 2005; Walker et al., 2010). Breast cancer treatment
history is important to this study, as chemotherapy and hormone treatment can have an
impact on memory in women with breast cancer, and a subset of women may be
susceptible to cognitive impairment following these treatments (Ahles et al., 2012; Ahles
& Saykin, 2007; Ahles et al., 2008; Bender et al., 2006; Castellon et al., 2004; Wefel et
al., 2004).
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Research Questions. The research questions and hypotheses in this study were
generated from the literature on acupuncture treatment for menopausal symptoms. The
primary outcome in these studies is usually reduction of vasomotor symptoms. Studies
where subjects received acupuncture resulted in an improvement in vasomotor
symptoms, often reaching a statistically significant decrease in severity and frequency.
Additionally, with the exception of a small randomized trial (Cohen et al., 2003), studies
that included control groups receiving control or sham needling not only found a
significant decrease in vasomotor symptoms in these groups, but were not able to show a
statistical difference between the symptom-specific and control acupuncture arms (Avis
et al., 2008; Deng et al., 2007; A. Vincent et al., 2007; Wyon et al., 1995; Wyon et al.,
2004; Zaborowska et al., 2007).
Frequency data from symptom diaries are typically used to evaluate change in
vasomotor symptoms in intervention studies. In this study, frequencies of loss of
concentration as a measure of memory were extracted from the Daily Symptom Diary for
a total of 21 days over a period of nine weeks. The diary was considered the best source
of data, as the two other instruments would each provide only 3 ratings of a single
memory measure.
Research Question 1. What are the effects of menopausal symptom-specific
acupuncture on memory in breast cancer survivors with menopausal symptoms?
Instruments. The three instruments that were used in the parent study to gather
symptom data included a measure of memory. The results of each are examined here.
Daily Symptom Diary. The Daily Symptom Diary did not yield significant results
from the analysis of loss of concentration frequencies. It is possible that examining
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frequency is not an adequate way to measure memory issues. Subjects‟ interpretation of
the term loss of concentration may not be sufficiently comprehensive to capture memory
changes that women experience in their daily activities such as difficulty recalling words,
forgetfulness, or difficulty thinking clearly. Or the term could be construed to mean
something more serious. This may have affected accuracy of reporting, as no definition
of the term was provided on the diary.
At the same time they were recording loss of concentration, women were also
recording frequency of mood changes and sleep disruption, as well as frequency and
severity of HF and night sweats on the diary. Making a number of entries in the diary
involving different symptom categories may interfere with accurate recall or recording.
The diary format is commonly used in menopause symptom studies for recording
frequency and severity of vasomotor symptoms alone (Guttuso Jr., DiGrazio, & Reddy,
2012; Sloan et al., 2001), with additional instruments employed for other symptom
assessments. No menopause studies have been found that include a memory measure as
part of a daily diary.
Kupperman Index. The results from the Kupperman Index were different from
the Daily Symptom Diary. As in the Daily Symptom Diary, the terminology for the
memory measure in the Kupperman Index is loss of concentration. But in this instrument,
severity rather than frequency is assessed with an immediate time frame for that day.
Symptoms are rated by the subjects on a scale from 0 to 3, yielding one report of loss of
concentration at each of the three time points. In this study, subjects responded verbally
to items on this instrument upon interview by the research assistant.
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Frequency distribution analysis of the ratings showed the proportion of change in
symptom scores to be significantly different between groups at all three time points. On
examination of pairwise comparisons, symptom severity scores in the enhanced usual
care group appeared to show greater improvement over time than those in the AP groups,
which is an unexpected finding.
The Kupperman Index is often included in studies to measure severity of
menopause symptoms. Psychometric evaluation of reliability and validity of the index is
sparse, but it may have face validity in that it appears to measure the symptoms (Alder,
1998). A “modified” version of the index is typically used, though the origin of the
modified version is difficult to trace. The exact modifications of the original index are not
clear and may vary from study to study. In studies that incorporate the modified index,
specific items on the instrument are not always identified. Nedstrand and associates
(2005) provide a description of 11 items on a modified Kupperman Index, with no
memory measure included. The list of symptoms on a “validated” Kupperman Index used
in another AP study was slightly different, but also did not include memory (Hervik &
Mjåland, 2009). Four of the 11 symptoms on the modified Kupperman Index are assigned
a weight used in calculation of a final sum score. Menopause symptom severity is
determined by the total score, and ratings of each individual symptom are not analyzed,
which is the approach typically used in the reporting of index results (Frisk et al., 2008;
Wyon et al., 1995; Wyon et al., 2004; Zaborowska et al., 2007). According to Alder
(1998), summing scores of diverse symptoms is not statistically valid as the Kupperman
Index has not been subjected to factor analysis.
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Our study examined the rating of loss of concentration alone, an unweighted
single item on the index which has been found on one modified version of the index. The
aforementioned version was developed for a trial of a new formulation of menopause
hormone therapy vs. placebo, and only total scores were reported (Gelfand et al., 2003).
Alder (1998) noted that the Kupperman Index does not meet current psychometric
standards, and that conclusions drawn from research based on this invalid instrument may
be unsound. Therefore, the usefulness of these results from the Kupperman Index may be
limited. Concerns about subjects‟ interpretation of the term loss of concentration are
described above.
Menopause-Specific Quality of Life Questionnaire. On this instrument, subjects
were asked if they have experienced poor memory. If so, the subject then rated the bother,
or severity, of the symptom in the past month on a scale of 0 to 6, producing one report of
symptom severity at each of the three time points. Subjects‟ verbal responses to the
MENQOL items were recorded by the research assistant.
The results from the MENQOL differed from those of the Daily Symptom Diary
and the Kupperman Index. Analysis of frequencies of the ratings showed a significant
difference in the proportion of change in symptom scores between groups, with
significant differences seen between all groups at all three time points in pairwise
comparisons. Symptom severity scores in both AP groups appeared to show greater
improvement over time than those in the enhanced usual care group. This is consistent
with the literature where both control acupuncture and symptom-specific acupuncture are
more effective than a non-acupuncture control in reducing frequency and severity of hot
flashes (Avis et al., 2008; Painovich et al., 2012; Wyon et al., 2004; Zaborowska et al.,
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2007). The positive trend toward improvement in the AP specific group compared to the
AP control group is not a typical finding in acupuncture and hot flash studies. With rare
exception (Hervik & Mjåland, 2009; Huang et al., 2006; Nir et al., 2007), control
acupuncture has not been found to be different in effect from symptom-specific
acupuncture in menopausal symptom studies.
There is ongoing discourse about the challenge of selecting an appropriate
acupuncture control (or sham) condition in acupuncture research. Most forms of sham
acupuncture have biophysical effects, and are not considered to be inert. A range of nonspecific mechanisms may be activated regardless of what needling techniques are used or
where needling occurs. Even if the effect of the acupuncture control is small, it may be
harder to discern a difference between true (verum) acupuncture and control acupuncture
(Birch, 2006; Langevin et al., 2006; C. Vincent & Lewith, 1995).
In the MENQOL, the time frame of symptom severity being reported is one
month, as opposed to one day, which could lead to more careful consideration of the
character of the symptom by the subject. The term experiencing poor memory is different
from that in the other instruments, and may be interpreted by the subjects as more
inclusive of the memory challenges women experience in daily functioning. This term
may prompt subjects to recall difficulties that originate from a different memory function
than that of loss of concentration. Recent studies of menopausal cognitive complaints
demonstrated a relationship between perceived symptoms and objective findings on
cognitive testing, with results suggesting that subjective memory difficulties during the
menopausal transition are associated with working memory and complex attention
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(Weber et al., 2012) as well as with verbal memory (Schaafsma et al., 2010; Weber &
Mapstone, 2009).
The measure of experiencing poor memory on the MENQOL is one of seven
items in the psychosocial domain, which includes self reported feelings of anxiety,
depression, dissatisfaction with life and wanting to be alone. It has not been assessed as
an individual item separate from the psychosocial domain in studies of acupuncture and
menopausal symptoms. In acupuncture studies that have included the MENQOL as a
measure, a significant decrease in symptom bother was found in the vasomotor domain,
but not in any other domain (Avis et al., 2008; Nir et al., 2007; Painovich et al., 2012). In
a factor-analytic evaluation of the MENQOL, poor memory was one of a few items found
that cross-loaded across more than one domain, and thus did not add statistical value to
the scoring of the psychosocial domain (Van Dole et al., 2012). An analysis of this single
memory measure, apart from the psychosocial domain, may be more informative about
treatment effects of acupuncture on cognitive change. However, the results from the
MENQOL in this study, while intriguing, may not be as sound as findings obtained with
a reliable and valid instrument that measures perception of everyday memory
functioning, such as the Memory Functioning Questionnaire (Gilewski, Zelinski, &
Schaie, 1990), or with objective neurocognitive testing.
Research Question 2. Is there a relationship between improvements in hot
flashes/night sweats and perceived memory changes in breast cancer survivors with
menopausal symptoms? No significant differences were seen over time between
treatment groups on frequency of loss of concentration episodes from the Daily Symptom
Diary. Further examination of the diary data using frequency distributions showed no
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significant differences when comparing group change in loss of concentration at any time
point. The proposed analysis for this question was considered in order to examine the
relationship of improvement in hot flashes/night sweats and memory using the MENQOL
data. A large proportion of subjects showed no change at each of the time points and
would be eliminated from the analysis, resulting in an insufficient number of subjects to
draw a meaningful conclusion. Based on these characteristics of the data, no further
analysis was undertaken.
Summary. Not all AP and menopause symptom studies include a measure of
memory. In addition to the instruments used to assess memory change in this study, there
are other quality of life scales seen in AP studies that include memory. The Menopause
Rating Scale (MRS) measures severity of aging symptoms and their impact on healthrelated quality of life. It is comprised of three dimensions: psychological, somatic and
urogenital. The psychological dimension includes a question on impaired memory (Berlin
Center for Epidemiology and Health Research, 2008; Heinemann et al., 2004). The MRS
was included in a study on the effects of AP on hot flashes in peri- and postmenopausal
women (Kim et al., 2010).
Another instrument used in AP studies is the Women‟s Health Questionnaire
(WHQ) which is a health-related quality of life measure for mid-life women and consists
of nine subscales, one of which is memory/concentration (Hunter, 1992, 2000). The
WHQ was used in the ACUFLASH study, a randomized trial comparing the effect of AP
and self-care on hot flashes in postmenopausal women (Borud et al., 2009; Borud et al.,
2010). Two studies on AP and vasomotor symptoms in breast cancer survivors used the
WHQ (de Valois et al., 2010; Frisk et al., 2012). After 8 weeks of AP in a single-arm,
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observational study, significant improvement from baseline was seen in the
memory/concentration subscale of the WHQ (de Valois et al., 2010). This is the only
acupuncture study found to date that shows specific improvement in the menopausal
symptom of memory changes using a quality of life scale.
While there were no statistically significant results from the Daily Symptom
Diary, some interesting trends were seen in the analysis of memory data from the
MENQOL in favor of AP over enhanced usual care, and an indication that more positive
change was seen in the AP specific group than in the AP control group. Though there are
inconsistencies in the literature, AP remains promising as a non-hormonal treatment for
menopausal symptoms, including memory difficulties, and merits further investigation.

Limitations of the Study
There are some recognized limitations to this study. The data on the variables
being measured were obtained by self-report, including medical and treatment history.
Self-report bias can lead to inaccurate responses, and over- or under-reporting of
symptoms. Self-reports may be influenced by misunderstanding of instructions by the
participants. However, self-report is a common and valid method used in studies of this
type, and objective measurements are not always possible to obtain. It is possible that the
results of this study are not representative of the larger population of breast cancer
survivors who are experiencing menopausal symptoms, though the demographic findings
appear to be comparable to similar studies in the literature.
This study is also limited because it is a secondary data analysis, and instruments
were selected to address other primary research questions. This may have limited further
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exploration and examination of the variable of memory. For example, there were no data
available on education and time since menopause, both of which may have some
influence on performance on cognitive measures. Additionally, a more detailed
examination of perceived memory functions with an instrument specific to this
menopausal symptom may have offered important information about the symptom
experience.

Implications for Practice
There are a large number of women affected by menopausal symptoms because of
natural or surgical menopause, or as a result of cancer treatment. As the number of breast
cancer survivors has increased, management of symptoms and their impact on quality of
life has become imperative for healthcare providers to address.
Following treatment for breast cancer, subtle cognitive impairment may exist in a
variety of cognitive domains. The menopausal symptom of cognitive difficulties can have
a negative impact on work, social and family relationships, and everyday activities
(Woods & Mitchell, 2011). Psychological distress and negative emotions can increase
women‟s‟ subjective evaluation of the severity of their symptoms (Thurston et al., 2008).
Recognition and acknowledgement of cognitive changes should be part of ongoing care.
Assessment tools to evaluate symptom distress should be used. Symptom clusters, which
include cognitive difficulty, have been identified for the breast cancer experience and
menopause transition that could be helpful in guiding interventions for multiple
symptoms often experienced concurrently (Bender et al., 2005; Cray, Woods, Herting, &
Mitchell, 2012). Interventions that support or improve memory function, including

104

alternative therapies, cognitive behavioral therapy (Ferguson et al., 2012), and cognitive
training (Von Ah et al., 2012), may have a positive impact on quality of life.
There is ongoing research into the potential underlying mechanisms of cognitive
impairment following a diagnosis of and treatment for breast cancer, as well as research
on pharmacologic and nonpharmacologic interventions. Healthcare providers need to
stay informed about advances and evolving evidence related to these areas (Von Ah,
Jansen, Allen, Schiavone, & Wulff, 2011).
Providers should be knowledgeable about complementary and alternative therapy
resources, and make informed and appropriate referrals to qualified practitioners (Smith
& Bauer-Wu, 2012). Women who have experienced a treatment-induced menopause, and
are taking a selective estrogen receptor modulator or an aromatase inhibitor, may not
want to take additional medication to manage menopausal symptoms. Pharmacologic
therapy with drugs such as antidepressants for menopausal vasomotor symptoms may
interact with adjunct hormonal therapy to reduce its effectiveness (Kelly et al., 2010).

Suggestions for Future Research
There is a need for effective, well-tolerated nonhormonal treatments for
menopausal symptoms, especially in women with breast cancer, yet there are few studies
designed to evaluate the effectiveness of interventions to treat cognitive changes. The
results of this study helped to identify areas of consideration for future research.
The results reinforce the need for cognitive measures that are more specific than
the questions and instruments used in this study. Objective, neuropsychological testing
should be included, which would allow analysis and comparison of objective and
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subjective memory data. A tool should be selected that measures self-perception of
everyday memory issues rather than single items or subscales of larger survey
instruments not specific to memory. This could avoid misinterpretation of the meaning of
broader questions. An example of a reliable and valid instrument is the Memory
Functioning Questionnaire (MFQ) (Gilewski et al., 1990). The MFQ is used in several
large studies, such as the Study of Women‟s Health Across the Nation, and the Seattle
Women‟s Health Study, as well as in studies on menopausal transition (Maki et al., 2007;
Weber & Mapstone, 2009; Weber et al., 2012). The MENQOL-Intervention scale could
be used in an acupuncture intervention trial (Lewis et al., 2005). Three items were added
to the physical subscale of the MENQOL, and the valid recall period for symptoms is one
week rather than one month. Results could then be more reliably compared to a Daily
Symptom Diary. Demographic data should include level of education. This is strongly
associated with cognitive performance, and can reveal increased risk for cognitive
impairment (Lezak, Howieson, Bigler, & Tranel, 2012). Memory should continue to be
examined in relationship to other menopausal symptoms and their response to
acupuncture with a goal to build evidence for a multisymptom intervention that could
address multiple symptoms without adverse effects.
In an acupuncture study, it would be interesting to include the Outcome
Credibility/Expectancy Questionnaire (Devilly & Borkovec, 2000). This would provide a
measure of subjects‟ expectations of treatment benefit and treatment credibility, and
assess whether the treatment and control interventions were adequately matched and
comparable in their psychological impact (Deng et al., 2007; Kim et al., 2010; Otte,
Carpenter, Zhong, & Johnstone, 2011; C. Vincent & Lewith, 1995). This is especially
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relevant considering the ongoing debate about a satisfactory acupuncture placebo (Birch,
2006; Lund & Lundeberg, 2006; C. Vincent & Lewith, 1995).

Conclusion
The primary purpose of this study was to examine the efficacy of acupuncture to
improve the menopausal symptom of memory changes in breast cancer survivors.
Analysis of the MENQOL data revealed more positive change in the acupuncture groups
in improvement of memory than in the enhanced usual care group. These findings
support the need for further exploration of targeted interventions such as acupuncture to
improve memory difficulties for menopausal women and breast cancer survivors,
particularly as advances are made in the understanding of the mechanisms of cognitive
change in these women.
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Appendix A
Demographic Data Form
Demographic Data Form
Menopause Symptom Relief for Women with Breast Cancer
Date

Participant #

Age_________DOB____________

Marital status________ Educational level____________Household income__________
Employment (FT/PT; type)______________________________________________
Children (gender & age)_________________________________________________
LMP _________ PMP

Date of/Age at Menopause___________________

Menstrual Cycle Changes: No Change______Cycles Longer______Cycles Shorter_______
Menopause: Natural ____ Related to Breast Cancer Treatment ____ Not Menopausal ____
HRT History:
1) Estrogen
2) Estrogen
3) Estrogen

Progestin
Progestin
Progestin

Other Hormones

Dates:
Dates:
Dates:
Dates:

Current Medications:
Breast Cancer Diagnosis ________________________________ Stage______________
Date of Breast Cancer Diagnosis___________ Lymph Node Involvement: Yes____ No____
Surgery:

1) ________________________ Date_______
2) ________________________ Date_______

Hormone Therapy_____________________Date Begun______ Date Ended_____
Chemotherapy _____________________

Date Begun______ Date Ended_____

Radiation

_______________________ Date Begun______ Date Ended_____

Other

_______________________ Date Begun______ Date Ended_____
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Demographic Data Form
Hot Flash Remedies
Date:
Participant #

Treatment

Details

Begun

Ended

Diet
Exercise
Meditation
Vitamins
Herbs
Visualization
Healing
Other
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Relief/Success
in Hot Flashes

Comments

Appendix B
Daily Symptom Diary
Daily Symptom Calendar
Daily Legend
Frequency (Freq):
Number of times per day symptom occurs

Day

1

Participant Number:
Dates:
Week Number:

Severity (Sev):
0 = NOT PRESENT
1 = MILD
2 = MODERATE
3 = SEVERE
2
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Freq Sev Freq

3
Sev Freq

4
Sev Freq

5
Sev Freq

6

7

Sev Freq Sev Freq

Hot flashes *
Night sweats*
Mood changes
Sleep disturbances
Loss of concentration
Events affecting
symptoms
*MILD -a warm sensation without sweating that leaves you able to continue your daily activity
MODERATE -a warm sensation associated with sweating that leaves you able to continue your daily activity
SEVERE -a hot sensation associated with sweating so intense that you have to stop your activity

Sev

Appendix C
Modified Kupperman Index
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Appendix D
Menopause-Specific Quality of Life Questionnaire (MENQOL)
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